Page last updated: 2024-12-05

pamidronate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Pamidronate is a bisphosphonate medication used to treat a variety of conditions, including osteoporosis, Paget's disease of bone, and multiple myeloma. It works by inhibiting the activity of osteoclasts, the cells responsible for bone resorption. Pamidronate is synthesized by a multi-step process that involves the reaction of a phosphorus-containing compound with a nitrogen-containing compound. The resulting product is then purified and formulated into a sterile solution for intravenous administration. Pamidronate has been shown to be effective in reducing bone resorption and increasing bone mineral density. It is also effective in reducing pain and fracture risk in patients with osteoporosis and Paget's disease of bone. Pamidronate is studied extensively due to its potential to treat a variety of bone diseases. Researchers are investigating the effects of pamidronate on bone metabolism, the mechanisms of action, and the potential for new drug development. '

Cross-References

ID SourceID
PubMed CID4674
CHEMBL ID834
CHEBI ID7903
SCHEMBL ID18361
MeSH IDM0071565

Synonyms (85)

Synonym
BIDD:GT0538
aminomux
3-amino-1-hydroxypropylidene-1,1-diphosphonate
(3-amino-1-hydroxy-1-phosphono-propyl)phosphonic acid
phosphonic acid, (3-amino-1-hydroxypropylidene)bis-
cgp-23339ae
(3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid)
HSCI1_000312
CHEMDIV1_025240
pamidronate ,
40391-99-9
C07395
pamidronic acid
NCGC00159433-03
DB00282
NCGC00159433-02
pamidronic acid [inn:ban]
(3-amino-1-hydroxypropylidene)diphosphonic acid
amidronate
einecs 254-905-2
acidum pamidronicum [inn-latin]
acido pamidronico [inn-spanish]
(3-amino-1-hydroxypropylidene)bisphosphonic acid
acide pamidronique [inn-french]
bdbm12581
chembl834 ,
bisphosphonate 6
jmc515594 compound 62
(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid
HMS2090C13
ribodroat
ribodroat (tn)
pamidronic acid (inn)
D07281
HMS658L06
AKOS003599275
dtxsid4023414 ,
dtxcid003414
cas-40391-99-9
tox21_111664
A825084
CCG-2075
106437-12-1
oyy3447omc ,
unii-oyy3447omc
acido pamidronico
acide pamidronique
acidum pamidronicum
FT-0630610
pamidronic acid [who-dd]
pamidronate [vandf]
pamidronic acid [inn]
3-amino-1-hydroxypropane-1,1-diphosphonic acid
dihydrogen (3-amino-1-hydroxypropylidene)diphosphonate
pamidronate [mart.]
pamidronic acid [mi]
S2063
gtpl7259
SCHEMBL18361
NCGC00165862-02
tox21_111664_1
CHEBI:7903
CS-7787
phosphonic acid, p,p'-(3-amino-1-hydroxypropylidene)bis-
propane-1-hydroxy-3-amino-1,1-diphosphonic acid
sr-01000514873
SR-01000514873-1
HY-B0012
3-amino-1-hydroxypropane-1,1-diyldiphosphonic acid
STL510914
BCP17709
Q627499
mfcd00168777
1159812-33-5
(3-amino-1-hydroxypropane-1,1-diyl)diphosphonic acid
HMS3749A11
C75045
EN300-119514
(3-amino-1-hydroxy-1-phosphono-propyl)-phosphonic acid
STARBLD0044121
acidum pamidronicum (inn-latin)
acide pamidronique (inn-french)
pamidronate (mart.)
acido pamidronico (inn-spanish)
m05ba03

Research Excerpts

Overview

Pamidronate is a bisphosphonate drug widely utilized in veterinary oncologic practice for the palliation of malignant osteolysis.

ExcerptReferenceRelevance
"Pamidronate is a safe and efficient method of CRMO therapy, particularly in cases refractory to NSAIDs treatment. "( Treatment of chronic recurrent multifocal osteomyelitis with bisphosphonates in children.
Bień, S; Błażkiewicz, M; Ebisz, M; Jurczyk, M; Namyślak, M; Sułko, J, 2019
)
1.96
"Pamidronate appears to be an effective treatment in children with CNO unresponsive to NSAIDs."( Efficacy of pamidronate therapy in children with chronic non-bacterial osteitis: disease activity assessment by whole body magnetic resonance imaging.
Finn, A; Ramanan, AV; Roderick, M; Shah, R, 2014
)
1.5
"Pamidronate is a bisphosphonate drug widely utilized in veterinary oncologic practice for the palliation of malignant osteolysis. "( Extravasation reactions associated with the administration of pamidronate: 11 cases (2008-2013).
Barber, LG; Clifford, CA; Correa, SS; LaDue, TA; Marker, BA; Mullin, CM; Sauerbrey, ML; Thalhofer, PL; Wood, CC, 2017
)
2.14
"Pamidronate appears to be an effective treatment in the osteo-articular manifestations of SAPHO syndrome. "( Sustained remission of SAPHO syndrome with pamidronate: a follow-up of fourteen cases and a review of the literature.
Colina, M; La Corte, R; Trotta, F,
)
1.84
"Pamidronate is a nitrogen-containing bisphosphonate with a potent inhibiting bone resorption effect that has been used to treat osteoporosis in children."( Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis.
Calvo Penades, I; Lopez Montesinos, B; Marco Puche, A,
)
1.11
"Pamidronate is an easy to use potent inhibitor of osteolysis, given in conjunction with standard anticancer therapies effectively relieves bone pain and improves performance status."( [Pamidronate in the treatment of bone metastases from breast cancer].
Gyuricska, A; Landherr, L; Nagykálnai, T; Zatkóné, GP, 2002
)
1.95
"Pamidronate is a symptomatic, noncurative treatment that does not correct the genetic abnormalities responsible for the histological bone alterations."( Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients.
Giraud, F; Meunier, PJ, 2002
)
1.32
"Pamidronate is a safe and useful treatment for corticoid-induced osteoporosis in the pediatric population."( Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children.
Alcover, E; González, E; Noguera, A; Pavía, C; Ros, JB; Valls, C; Villaronga, M,
)
1.57
"Pamidronate appears to be an effective and well-tolerated therapeutic option for patients with fibrous dysplasia. "( Treatment of monostotic fibrous dysplasia with pamidronate.
Godzinski, J; Klempous, J; Kos, M; Luczak, K, 2004
)
2.02
"Pamidronate seems to be a very effective mode of therapy for patients with the SAPHO syndrome, by promoting remission in all components of the disorder, such as bone, joint and skin involvement, and ceases the bouts that characterize this disorder."( SAPHO syndrome treated with pamidronate: an open-label study of 10 patients.
Aamar, S; Amital, H; Applbaum, YH; Daniel, N; Rubinow, A, 2004
)
2.06
"Pamidronate is a bisphosphonate that is effective in treating bone disease including osteopenia and osteoporosis in adults. "( Determination of pamidronate in human whole blood and urine by reversed-phase HPLC with fluorescence detection.
Acott, PD; Crocker, JF; O'Regan, PA; Renton, KW; Wong, JA, 2004
)
2.11
"Pamidronate is a second-generation bisphosphonate that affects bone turnover and demonstrates anti-inflammatory properties."( Pamidronate in the treatment of childhood SAPHO syndrome.
Beresford, MW; Cleary, AG; Davidson, JE; Kerrison, C, 2004
)
2.49
"Pamidronate is a second-generation bisphosphonate that has been used to attenuate post-renal transplant bone loss, but its effect on the function of the renal allograft is unclear. "( Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction.
Coco, M; Glicklich, D; Lee, S, 2004
)
3.21
"Pamidronate is a representative of bisphosphonates, which are effectively used in the treatment of bone diseases. "( Effect of pamidronate on the action of catecholamines on blood pressure in the marrow cavity of long bones in rats with prednisolone-induced osteoporosis.
Cegieła, U; Folwarczna, J; Kaczmarczyk-Sedlak, I; Nowińska, B,
)
1.98
"Pamidronate is a second generation bisphosphonate that has been used in Europe for the treatment of Paget's disease of bone for several years. "( Effects of intravenous pamidronate therapy on Paget's disease of bone.
Bombassei, GJ; Raisz, LG; Yocono, M, 1994
)
2.04
"Pamidronate (APD) is a new drug in the treatment of osteolytic bone diseases. "( Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport.
Brill, H; de Water, R; den Hartigh, J; Ramp-Koopmanschap, W; Sparidans, R; Twiss, IM; Vermeij, P; Wijdeveld, M, 1994
)
2.05
"Pamidronate (APD) is a bisphosphonate that prevents bone loss from a variety of causes. "( Parenteral pamidronate prevents thyroid hormone-induced bone loss in rats.
Dresner-Pollak, R; Greenspan, SL; Gundberg, C; Hock, JM; Maitland, LA; Middlebrooks, VL; Moses, AC; Rosen, HN; Sullivan, EK; Zeind, AJ, 1993
)
2.12
"Pamidronate is an effective pharmacological agent and should be considered as primary therapy for this syndrome."( Hypercalcaemia in an immobilised patient with pneumonia.
Mark, S,
)
0.85
"Pamidronate is a potent biphosphonate which modulates tumour-induced osteolysis (TIO) by inhibiting osteoclast-mediated bone resorption. "( Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer.
Bruning, PF; Ford, JM; Mauriac, L; May-Levin, F; Rose, C; Soukop, M; Tyrrell, CT, 1995
)
3.18
"Pamidronate (APD) is a drug widely used for the treatment of hypercalcemia of malignancy. "( Safety of pamidronate in patients with renal failure and hypercalcemia.
Flombaum, CD; Machado, CE, 1996
)
2.14
"Pamidronate disodium is a second-generation biphosphonate, a group of compounds that are being used increasingly to inhibit bone resorption in disorders that are characterized by excessive bone loss such, as hypercalcemia of malignancy, osteoporosis, and Paget's disease. "( Sclerosis of lytic metastatic bone lesions during treatment with pamidronate in a patient with adenocarcinoma of unknown primary site.
Ford, JM; Fuji, T; Fushimi, H; Tanaka, M, 1996
)
1.97
"Pamidronate is a safe, welltolerated, and effective treatment for Paget's disease."( Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
Bhagat, CI; Gutteridge, DH; Kent, GN; Nicholson, GC; Price, RI; Prince, RL; Retallack, RW; Stewart, GO; Stuckey, BG; Thompson, RI; Ward, LC, 1996
)
1.23
"Pamidronate is a second generation bisphosphonate used for treating tumor-induced hypercalcemia and for preventing the development of new bone metastasis. "( [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma].
Arima, K; Hioki, T; Kawamura, J; Kise, H; Kobayashi, K; Sugiura, Y; Tochigi, H; Yanagawa, M, 1996
)
2.13
"Pamidronate is a second-generation bisphosphonate that undergoes negligible biodegradation and is eliminated exclusively by renal excretions. "( Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function.
Berenson, JR; Knight, RD; Kowalski, MO; Lau, HS; Rosen, L; Seaman, JJ; Sioufi, A; Vescio, R; Woo, M, 1997
)
2.06
"Pamidronate appears to be an effective therapy for HPOA. "( The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA).
Francis, H; Nicklason, F; Speden, D; Ward, J, 1997
)
2.13
"Pamidronate is a second-generation aminobisphosphonate that is a much more potent inhibitor of osteoclastic activity."( Bisphosphonates and breast carcinoma.
Lipton, A, 1997
)
1.02
"Pamidronate (APD) is a potent inhibitor of bone resorption that is useful in the management of patients with osteolytic bone metastases from breast cancer or multiple myeloma, tumour-induced hypercalcaemia or Paget's disease of bone. "( Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Coukell, AJ; Markham, A, 1998
)
3.19
"Pamidronate is a useful adjunct to standard chemotherapy in the palliative treatment of metastatic breast cancer."( Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
Blayney, D; Heffernan, M; Hortobagyi, GN; Knight, RD; Lipton, A; Mellars, K; Porter, L; Reitsma, DJ; Seaman, JJ; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1998
)
1.25
"Pamidronate is an effective drug used not only in patients with tumor-associated hypercalcemia, but also in normocalcemic patients with metastatic bone disease to relieve pains. "( Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.
Alakavuklar, M; Biberoglu, S; Cömlekçi, A; Hekimsoy, Z; Okan, I; Pişkin, O; Sekeroglu, B, 1998
)
1.94
"Pamidronate appears to be an effective and well tolerable treatment option for patients with fibrous dysplasia."( [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
Pfeilschifter, J; Ziegler, R, 1998
)
2.13
"Pamidronate disodium is a second-generation bisphosphonate capable of inhibiting bone resorption (particularly osteoclast activity) without affecting bone remineralization."( Role of pamidronate disodium in the treatment of metastatic bone disease.
Casuccio, A; De Conno, F; Fulfaro, F; Ripamonti, C; Ticozzi, C,
)
1.29
"Pamidronate is a bisphosphonate that is efficacious in the treatment of symptomatic bone metastases and can be considered an important therapeutic option in association with systemic treatments, radiotherapy and normal supportive care, especially in patients with breast cancer and multiple myeloma. "( Role of pamidronate disodium in the treatment of metastatic bone disease.
Casuccio, A; De Conno, F; Fulfaro, F; Ripamonti, C; Ticozzi, C,
)
2.01
"Pamidronate is an effective inhibitor of bone resorption; for this reason it is used in the treatment of high bone turnover diseases and osteoporosis. "( [Treatment of post menopausal osteoporosis with intravenous pamidronate in patients with esophagogastric pathology].
Fradinger, E; Morillo, S; Rey, P; Sarli, M; Zanchetta, J, 1998
)
1.99
"Pamidronate is a potentially useful antidote against CCF toxicosis in dogs."( Use of pamidronate to reverse vitamin D3-induced toxicosis in dogs.
Braselton, WE; Chiapuzio, CL; Fitzgerald, SF; Kaneene, JB; Kruger, JM; Nachreiner, RF; Rumbeiha, WK, 1999
)
2.2
"Pamidronate is a bisphosphonate whose short-term biological efficacy in Paget's disease of bone was convincingly established many years ago. "( Effect of multiple intravenous pamidronate courses in Paget's disease of bone.
Arlot, M; Meunier, PJ; Thevenon, J; Trombetti, A; Uebelhart, B, 1999
)
2.03
"Pamidronate disodium is a potentially useful drug to reduce CCF-induced toxicosis and other causes of hypercalcemia associated with increased bone resorption in dogs."( Use of pamidronate disodium to reduce cholecalciferol-induced toxicosis in dogs.
Braselton, WE; Fitzgerald, SD; Frese, KK; Kaneene, JB; Kruger, JM; Nachreiner, R; Rumbeiha, WK, 2000
)
2.2
"Pamidronate treatment is an effective therapeutic modality for children with polyostotic fibrous dysplasia, with a good short-term safety profile. "( Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
O'Sullivan, M; Zacharin, M, 2000
)
2.13
"Pamidronate, which is a member of the class of bisphosphonates, is widely used in the treatment of hypercalcemia of malignancy and osteolytic metastases."( Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
Appel, GB; D'Agati, VD; Dratch, AD; Fenves, AZ; Fine, PL; Jagannath, S; Kuhn, JA; Loon, NR; Markowitz, GS, 2001
)
1.26
"Pamidronate is a second-generation bisphosphonate used in the treatment of tumor-induced hypercalcemia and in the management of bone metastases from breast cancer, myeloma, or prostate cancer. "( Pharmacokinetics of pamidronate in patients with bone metastases.
Bauer, J; Burckhardt, P; Flesch, G; Ford, JM; Hauffe, S; Hess, U; Leyvraz, S, 1992
)
2.05

Effects

Pamidronate therapy has a positive impact on functional parameters including improved energy, decreased bone pain, and increased ambulation. The drug has a palliative effect in control of pain and may delay the natural history of bony collapse in the acute phase of ON.

Pamidronate has been demonstrated to be an effective agent in the treatment of cancer-associated hypercalcaemia. The drug has not been previously reported to cause tissue injury upon extravasation in dogs. Pamidronates is a safe and readily available option for clinical trials to treat H7N9 infection.

ExcerptReferenceRelevance
"Pamidronate has a beneficial effect in those patients with IIH where glucocorticoids and furosemide fail to meet the expectations."( Intravenous pamidronate in the treatment of severe idiopathic infantile hypercalcemia.
Bayer, M; Cerna, L; Konrad, M; Kutilek, S; Schlingmann, KP; Skalova, S, 2013
)
1.49
"Pamidronate treatment has a palliative effect in control of pain and may delay the natural history of bony collapse in the acute phase of ON, especially in early treated patients, but does not prevent late bone collapse and joint destruction in corticosteroid treated patients with ALL. "( Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes.
Nguyen, T; Zacharin, MR, 2006
)
3.22
"Pamidronate therapy has a positive impact on functional parameters including improved energy, decreased bone pain, and increased ambulation."( Experience with bisphosphonates in osteogenesis imperfecta.
Glorieux, FH, 2007
)
1.06
"Pamidronate has a pharmacologic profile similar to that of etidronate, but pamidronate is more potent and has a longer duration of effect. "( Pamidronate.
Kellihan, MJ; Mangino, PD, 1992
)
3.17
"Pamidronate has a beneficial effect in those patients with IIH where glucocorticoids and furosemide fail to meet the expectations."( Intravenous pamidronate in the treatment of severe idiopathic infantile hypercalcemia.
Bayer, M; Cerna, L; Konrad, M; Kutilek, S; Schlingmann, KP; Skalova, S, 2013
)
1.49
"Pamidronate (PAM) has been widely used for this purpose because of its high binding affinity toward bone and remarkable therapeutic effects."( Charge and hydrophobicity effects of NIR fluorophores on bone-specific imaging.
Bao, K; Choi, HS; Gibbs, SL; Gravier, J; Hyun, H; Lee, JH; Nasr, KA, 2015
)
1.14
"As pamidronate has been used for osteoporosis treatment for more than 20 years, pamidronate-based therapy represents for a safe and readily available option for clinical trials to treat H7N9 infection."( The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice.
Chan, JF; Chan, KH; Chen, H; Lam, KT; Lau, SY; Lau, YL; Li, L; Liu, M; Liu, Y; To, KK; Tu, W; Wu, WL; Xiang, Z; Yuen, KY; Zheng, J, 2015
)
1.23
"Pamidronate has not been previously reported to cause tissue injury upon extravasation in dogs."( Extravasation reactions associated with the administration of pamidronate: 11 cases (2008-2013).
Barber, LG; Clifford, CA; Correa, SS; LaDue, TA; Marker, BA; Mullin, CM; Sauerbrey, ML; Thalhofer, PL; Wood, CC, 2017
)
1.42
"Pamidronate has no effect on intestinal epithelial cells in vitro in terms of cytokine/chemokine release, but enhances IFN-γ, IL-6, and IL-10 production by T cells in coculture."( The Bisphosphonate Pamidronate is an Intestinal Antiinflammatory Agent in Rat and Mouse Experimental Colitis.
González, R; López-Posadas, R; Martínez-Augustin, O; Mascaraque, C; Sánchez de Medina, F; Suárez, MD; Zarzuelo, A, 2016
)
1.48
"Pamidronate (PAM), which has to be administered as a 3-day course according to the original protocol by Glorieux, is the most frequently used therapy."( Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta.
Beccard, R; Demant, A; Fricke, O; Koerber, F; Palmisano, D; Schoenau, E; Semler, O, 2011
)
1.33
"Pamidronate has been demonstrated to decrease bone-related complications in multiple myeloma and delay progression of the disease. "( Podocyte injury associated glomerulopathies induced by pamidronate.
Abulezz, SR; Barri, YM; Bonsib, SM; Munshi, NC; Sukumalchantra, S; Walker, PD; Wallach, J, 2004
)
2.01
"Pamidronate has been mainly associated with collapsing focal segmental glomerulosclerosis. "( Podocyte injury associated glomerulopathies induced by pamidronate.
Abulezz, SR; Barri, YM; Bonsib, SM; Munshi, NC; Sukumalchantra, S; Walker, PD; Wallach, J, 2004
)
2.01
"Pamidronate has good curative effects in treating pain induced by bone metastasis. "( [Pamidronate in treatment of pain caused by bone metastasis].
Cai, Y; Chen, YL; Liu, HQ; Liu, MZ; Ren, J; Wang, DJ; Zhan, QY, 2004
)
2.68
"Pamidronate has recently been used in SAPHO syndrome due to its anti-osteoclastic effect. "( The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome.
Duquesnoy, B; Gerot, I; Grange, L; Puechal, X; Sibilia, J; Solau-Gervais, E; Sordet, C; Soubrier, M, 2006
)
2.01
"Pamidronate treatment has a palliative effect in control of pain and may delay the natural history of bony collapse in the acute phase of ON, especially in early treated patients, but does not prevent late bone collapse and joint destruction in corticosteroid treated patients with ALL. "( Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes.
Nguyen, T; Zacharin, MR, 2006
)
3.22
"Pamidronate has been poorly studied in this population."( Metabolic bone disease in patients receiving home parenteral nutrition: a Canadian study and review.
Aghdassi, E; Allard, JP; Baun, M; Fairholm, L; Raman, M; Saqui, O; Yeung, M,
)
0.85
"Pamidronate treatment has been shown to improve outcome in osteogenesis imperfecta (OI); however, factors influencing outcome are unclear. "( Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome.
Bajpai, A; Ghosh, M; Gupta, N; Kabra, M; Sharda, S, 2007
)
2.16
"Pamidronate has been studied as a therapeutic drug for various osteopenic diseases. "( Inhibition of bone healing by pamidronate in calvarial bony defects.
Cho, BO; Cho, M; Choi, JY; Kim, HJ; Kim, SG; Lee, YC; Seong, HS, 2007
)
2.07
"Pamidronate therapy has a positive impact on functional parameters including improved energy, decreased bone pain, and increased ambulation."( Experience with bisphosphonates in osteogenesis imperfecta.
Glorieux, FH, 2007
)
1.06
"Pamidronate (Aredia) has been used in the treatment of hypercalcemia of malignancy, in Paget's disease of bone, and in osteoporosis to prevent bone resorption. "( Effect of pamidronate on the mechanical properties of canine bone.
Acito, A; Grynpas, MD; Kasra, M, 1994
)
2.13
"Pamidronate has previously been reported to induce sclerosis of lytic bone metastases in patients with breast cancer."( Sclerosis of lytic metastatic bone lesions during treatment with pamidronate in a patient with adenocarcinoma of unknown primary site.
Ford, JM; Fuji, T; Fushimi, H; Tanaka, M, 1996
)
1.25
"Pamidronate has been found to be effective in reducing skeletal morbidity associated with bone metastases in both multiple myeloma and breast carcinoma patients when given intravenously, but is ineffective orally in multiple myeloma patients."( Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000
)
1.03
"Pamidronate has no influence on bone histomorphometry in this case."( [Effect of growth hormone on the structure of bone spongiosa in rats].
Kapitola, J; Povýsil, C; Zák, J, 1999
)
1.02
"Pamidronate has dose-dependent therapeutic properties in AS."( A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
Aaron, SL; Chiu, P; Davis, P; Fitzgerald, AA; Homik, J; Jhangri, GS; LeClercq, S; Maksymowych, WP; Russell, AS; Sholter, D; Skeith, KJ; Yan, A, 2002
)
1.98
"Pamidronate has a pharmacologic profile similar to that of etidronate, but pamidronate is more potent and has a longer duration of effect. "( Pamidronate.
Kellihan, MJ; Mangino, PD, 1992
)
3.17
"Pamidronate has been demonstrated to be an effective agent in the treatment of cancer-associated hypercalcaemia. "( A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia.
Boyle, IT; Cowan, RA; Dryburgh, FJ; Fraser, WD; Gallacher, SJ; Logue, FC; Ralston, SH, 1991
)
2

Actions

Pamidronate displays selective anti-AML activity by preferentially inhibiting survival and colony formation of AML CD34. The drug can cause vision-threatening diseases, which may require discontinuing the drug in some uveitis cases and, in this series, all cases of scleritis.

ExcerptReferenceRelevance
"Pamidronate displays selective anti-AML activity by preferentially inhibiting survival and colony formation of AML CD34"( Prenylation-dependent Ras inhibition by pamidronate inhibits pediatric acute myeloid leukemia stem and differentiated cell growth and survival.
He, R; Li, J; Liu, X; Pan, R; Wang, C, 2019
)
1.5
"Pamidronate did not increase cortical thickness or cortical area/total area relative to control mice."( Effect of bisphosphonates on the rapidly growing male murine skeleton.
Bouxsein, ML; Brooks, DJ; Demay, MB; Louis, L; Zhu, ED, 2014
)
1.12
"Pamidronate did not inhibit MMP-2 activation but attenuated oxidative stress and improved myocardial energetic metabolism."( Pamidronate Attenuates Oxidative Stress and Energetic Metabolism Changes but Worsens Functional Outcomes in Acute Doxorubicin-Induced Cardiotoxicity in Rats.
Alegre, PH; Antonio, L; Azevedo, PS; Bergamasco, CM; Carvalho, PB; Fernandes, AA; Gonçalves, AF; Minicucci, MF; Modesto, PN; Paiva, SA; Polegato, BF; Roscani, MG; Zornoff, M, 2016
)
2.6
"Pamidronate did not increase the risk of serious adverse events."( Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
Barrios, C; Casafont, F; Clemente, G; De la Mata, M; García-González, M; Guañabens, N; Monegal, A; Navasa, M; Serrano, T; Suárez, F; Suárez, MJ; Tome, S; Torne, S, 2009
)
2.52
"Pamidronate can rarely cause (collapsing) focal segmental glomerular sclerosis with the nephrotic syndrome and renal insufficiency. "( Renal complications from bisphosphonate treatment.
Hirschberg, R, 2012
)
1.82
"Pamidronate disodium can cause vision-threatening diseases, which may require discontinuing the drug in some uveitis cases and, in this series, all cases of scleritis."( Scleritis and other ocular side effects associated with pamidronate disodium.
Fraunfelder, FT; Fraunfelder, FW; Jensvold, B, 2003
)
1.29
"Pamidronate does not inhibit the gene expression of the putative tooth eruption molecules, colony-stimulating factor-1 and c-fos, both of which are expressed in the dental follicle, the tissue that is required for eruption to occur."( Inhibition of tooth eruption in the rat by a bisphosphonate.
Grier, RL; Wise, GE, 1998
)
1.02

Treatment

Pamidronate did not influence the concentration of beta2-microglobulin in Paget's disease bone. Treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia.

ExcerptReferenceRelevance
"Pamidronate treatment significantly increased the Z score in all patients, and increases in the Z score did not correlate with the OI types, causative genes, or genotype."( Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta.
Fujiwara, I; Kanno, J; Kure, S; Saito-Hakoda, A, 2018
)
1.54
"Pamidronate treatment stimulated the onset of recovery phase reducing fracture rate and permanent disabilities without evidence of side-effects."( Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: comparison with untreated patients.
Baroncelli, GI; Bertelloni, S; Erba, P; Giuca, MR; Vierucci, F; Zampollo, E, 2013
)
2.55
"Pamidronate-treated subjects showed a statistically significant difference with a median gain in BMD of 0.029 gm/cm in the lumbar spine compared with the control group, which showed a median loss of 0.025 gm/cm."( Prevention of postoperative osteopenia using IV pamidronate: a pilot study.
Dominguez-Bartmess, S; Hobby, BD; Szalay, EA,
)
1.11
"Pamidronate treatment had positive effects on skeletal muscle in the Mdx mice with decreased serum and muscle creatine kinase and evidence of improved muscle histology and grip strength."( Positive effects of bisphosphonates on bone and muscle in a mouse model of Duchenne muscular dystrophy.
Grynpas, MD; Mitchell, J; Sugamori, KS; Yoon, SH, 2016
)
1.16
"Pamidronate treatment in children with all types of OI increased LS BMD, decreased fracture rate, and improved vertebral compression fractures. "( Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Åström, E; Grigelioniene, G; Kindmark, A; Lindahl, K; Ljunggren, Ö; Malmgren, B; Rubin, CJ; Söderhäll, S, 2016
)
2.08
"Pamidronate treatment of G11-Tg mice restored the trabecular bone loss phenotype, as bone mineral density, bone volume, trabecular number, separation, and expressions of osteoblastic and osteoclastic genes were comparable with WT parameters."( Elevated Gα11 expression in osteoblast lineage cells promotes osteoclastogenesis and leads to enhanced trabecular bone accrual in response to pamidronate.
Dela Cruz, A; Grynpas, MD; Mitchell, J, 2016
)
1.36
"Pamidronate treatment protected mice from cortical bone loss but did not increase bone strength."( Prophylactic pamidronate partially protects from glucocorticoid-induced bone loss in the mdx mouse model of Duchenne muscular dystrophy.
Chen, J; Grynpas, MD; Mitchell, J; Yoon, SH, 2016
)
1.52
"Pamidronate-treated type III/IV and oral bisphosphonate-treated type I patients showed significant increases in total-hip BMD (0.006 [P = 0.003] and 0.011 [P = 0.046] gm/cm(2)/year, respectively)."( Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Gillen, C; Nunes, M; Shapiro, JR; Thompson, CB; Wu, Y, 2010
)
1.08
"Pamidronate treatment lowered the rate of fracture, and a 1-year course appears to provide a protective effect after treatment ends. "( Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy.
Bachrach, SJ; Harcke, HT; Hossain, J; Kecskemethy, HH, 2010
)
2.06
"Pamidronate treatment with vitamin D sufficiency can be effective therapy for the skeletal disease caused by the OPG deficiency form of JPD."( Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation.
Karamizadeh, Z; McAlister, WH; Mumm, S; Nasirabadi, S; Saki, F; Whyte, MP, 2013
)
1.11
"Pamidronate treatment can be considered a favorable therapeutic option for patients with MAS."( Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002
)
2.48
"Pamidronate treatment was associated with an increase in bone mineral density and may be an effective treatment modality for the management of osteoporosis in children with Menkes disease."( Pamidronate treatment improves bone mineral density in children with Menkes disease.
Boneh, A; Kanumakala, S; Zacharin, M, 2002
)
2.48
"Pamidronate treatment led to significant increases in bone mineral density (BMD), measured by DXA, in the lumbar spine at 12 months (P = 0.05) and in the femur neck (P = 0.02) at 24 months."( The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
Bober, M; Ernest, K; Fedarko, N; Gelman, R; McCarthy, EF; Rossiter, K; Santiago, HT; Shapiro, JR, 2003
)
1.34
"Pamidronate treatment suppresses excretion of total DPD."( Effect of pamidronate on excretion of pyridinium crosslinks of collagen after total hip arthroplasty.
Eastell, R; Jackson, B; Wilkinson, JM, 2003
)
1.44
"Pamidronate treatment was associated with development of adynamic bone histology."( Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate.
Bognar, I; Burris, L; Coco, M; Durkin, P; Faugere, MC; Figueroa, K; Glicklich, D; Greenstein, S; Malluche, H; McDonough, P; Schechner, R; Tellis, V; Wang, G, 2003
)
1.26
"Pamidronate treatment significantly influences the restoration of vertebral fractures in children with primary osteoporosis. "( Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry.
Körber, F; Land, C; Rieger-Wettengl, G; Schoenau, E; Stabrey, A; Sumník, Z, 2004
)
2.17
"Pamidronate (30 mg per treatment) or placebo was given at 3-month intervals for 12 months."( Effect of pamidronate on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy.
Hahn, JS; Kim, SH; Lim, SK, 2004
)
1.45
"Pamidronate treatment (60 mg/day for 3 days) was repeated in patients without evidence of PDB remission at day 120."( Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Mossetti, G; Nunziata, V; Rendina, D; Sorrentino, M; Viceconti, R, 2004
)
1.39
"Pamidronate treatment reduced tumor burden as assessed at autopsy by imaging and biomarkers."( Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP.
Barken, I; Burton, DW; Deftos, LJ; Geller, J; Hastings, RH; Hoffman, RM; Jiang, P; Yang, M, 2005
)
1.05
"Pamidronate treatment exhibited anti-tumor effects that were reflected by decreases in serum PTHrP, OPG, and by GFP and radiological imaging procedures. "( Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP.
Barken, I; Burton, DW; Deftos, LJ; Geller, J; Hastings, RH; Hoffman, RM; Jiang, P; Yang, M, 2005
)
1.77
"Pamidronate treatment was associated with delayed healing after osteotomy, but not after fracture."( Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate.
Fassier, F; Glorieux, FH; Munns, CF; Rauch, F; Zeitlin, L, 2004
)
1.26
"Pamidronate treatment improves bone quality in children with mild types of OI. "( Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
Kanumakala, S; Zacharin, M, 2004
)
3.21
"Pamidronate treatment has a palliative effect in control of pain and may delay the natural history of bony collapse in the acute phase of ON, especially in early treated patients, but does not prevent late bone collapse and joint destruction in corticosteroid treated patients with ALL. "( Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes.
Nguyen, T; Zacharin, MR, 2006
)
3.22
"Pamidronate treatment was associated with an increase in vertebral height ratio at each of the 12 sites that were analyzed."( Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
Glorieux, FH; Land, C; Munns, CF; Rauch, F; Sahebjam, S, 2006
)
1.27
"Pamidronate treatment of the patient also reduced the number of synovial fluid macrophages and resulted in less osteoclast formation and lacunar resorption."( Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
Adamopoulos, IE; Athanasou, NA; Edwards, JR; Ferguson, DJ; Wordsworth, PB, 2006
)
1.06
"Pamidronate treatment has been shown to improve outcome in osteogenesis imperfecta (OI); however, factors influencing outcome are unclear. "( Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome.
Bajpai, A; Ghosh, M; Gupta, N; Kabra, M; Sharda, S, 2007
)
2.16
"Pamidronate treatment was reinstituted in five of these patients at the end of 1.5 years."( Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
Alikasifoglu, A; Andiran, N; Gonc, N; Kandemir, N; Ozon, A; Yordam, N, 2008
)
1.52
"Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity. "( Palliative pamidronate treatment in patients with bone metastases from breast cancer.
Beex, LV; Bijvoet, OL; Blijham, G; Cleton, FJ; Hermans, J; Kroon, HM; Neijt, JP; Papapoulos, SE; Sleeboom, HP; van Holten-Verzantvoort, AT, 1993
)
2.12
"Pamidronate treatment resulted in a rapid and sustained reduction in urinary calcium and hydroxyproline excretions. "( Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study.
Breedveld, FC; Dijkmans, BA; Eggelmeijer, F; Papapoulos, SE; van Paassen, HC, 1994
)
1.98
"Pamidronate treatment in patients with Paget's disease of bone is effective and safe."( [Paget's disease of bone and treatment with pamidronate].
Stĕpán, J; Wilczek, H, 1993
)
1.27
"Pamidronate treatment resulted in a brisk reduction in plasma calcium concentration."( Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate.
Davies, M; Marks, JS; Mawer, EB; Selby, PL, 1995
)
1.23
"Pamidronate treatment for Paget's disease of bone leads to a sustained inhibition of elevated bone turnover."( [Bisphosphonate therapy of Paget's disease of bone with pamidronate].
Grauer, A; Klar, B; Knaus, J; Scharla, SH; Ziegler, R, 1996
)
1.98
"Pamidronate treatment increased secondary cancellous bone but could not restore normal growth-induced periosteal bone apposition and bone strength."( Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats.
Fukumoto, S; Fuse, H; Kawahara, H; Kodama, Y; Kurokawa, T; Matsumoto, T; Nakamura, T; Nakayama, K; Sekiguchi, C; Takahashi, H, 1997
)
1.3
"Pamidronate treatment did not influence the concentration of beta2-microglobulin and assessment of beta2-microglobulin in Paget's disease bone is no asset."( [Is beta 2-microglobulin a marker of bone remodeling in Paget's disease of bone?].
Wilczek, H, 1997
)
1.02
"Pamidronate treatment was also significantly associated with prolonged survival."( In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
Aparicio, A; Berenson, J; Gardner, A; Lichtenstein, A; Savage, A; Tu, Y, 1998
)
1.02
"Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia."( Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998
)
1.37
"Pamidronate treatment was followed by a significant increase in median body temperature at the 10-hour measurement and a significant decrease in counts of circulating lymphocytes, natural killer cells, T cells, and CD4+ and CD8+ T-cell subsets."( Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations.
Horn, E; Jilch, R; Keck, AV; Pecherstorfer, M; Sauty, A; Thiebaud, D; Zimmer-Roth, I, 2000
)
1.28
"Pamidronate treatment can ameliorate the course of bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome."( Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
Bertelloni, S; Buzi, F; de Sanctis, C; Lala, R; Matarazzo, P; Rigon, F, 2000
)
2.47
"Pamidronate treatment in severely affected OI patients under 3 yr of age is safe, increases BMD, and decreases fracture rate."( Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.
Bishop, NJ; Glorieux, FH; Montpetit, K; Plotkin, H; Rauch, F; Ruck-Gibis, J; Travers, R, 2000
)
2.47
"Pamidronate-treated bone marrow (BM) cultures of 24 patients with MM showed significantly reduced plasma cell survival compared with untreated cultures, especially in cultures in which activation of BM-gamma delta T cells was evident (14 of 24 patients with MM)."( Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.
Bauer, E; Feurle, J; Kunzmann, V; Tony, HP; Weissinger, F; Wilhelm, M, 2000
)
1.03
"Pamidronate treatment is an effective therapeutic modality for children with polyostotic fibrous dysplasia, with a good short-term safety profile. "( Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
O'Sullivan, M; Zacharin, M, 2000
)
2.13
"Pamidronate treatment seemed to increase trabecular bone density, although it was not effective in maintaining the AWcc of the operated extremity. "( Pamidronate increases trabecular bone mineral density in immobilization osteopenia in male rats.
Alhava, E; Arnala, I; Huuskonen, J; Olkkonen, H, 2001
)
3.2
"Pamidronate treatment of severe forms of OI is an effective therapeutic modality to increase bone density, decrease fracture rate, increase mobility and improve quality of life, irrespective of the severity of the mutation or clinical phenotype. "( Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
Bateman, J; Zacharin, M, 2002
)
3.2
"The treatment of pamidronate disodium combined with calcium based on the mobile terminal platform for the Internet of Things can reduce the severity of pain in elderly patients with osteoporosis and improve the BMD, which has a generalization value."( Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things.
Bai, Z; Guo, P; Kang, M; Wang, D; Wang, J, 2022
)
1.45
"Treatment with pamidronate resulted in only a slight enhancement of mineralization."( Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation.
Blouin, S; Fratzl-Zelman, N; Glorieux, FH; Klaushofer, K; Marini, JC; Rauch, F; Roschger, P, 2017
)
0.79
"Treatment with pamidronate is beneficial for the patient, family and society, increases mobility and bone density, improves quality of life and reduces family dependence in children with OI."( Therapy with pamidronate in children with osteogenesis imperfecta.
Brad, GF; Mang, N; Marginean, O; Mozos, I; Tamasanu, RC, 2017
)
1.16
"Treatment with pamidronate provides both symptomatic relief as well as normalisation of bone morphology."( Treatment of chronic recurrent multifocal osteomyelitis with bisphosphonates in children.
Bień, S; Błażkiewicz, M; Ebisz, M; Jurczyk, M; Namyślak, M; Sułko, J, 2019
)
0.85
"Pretreatment with pamidronate, but not with ibandronate or alendronate, improves chemically induced trinitrobenzenesulfonic acid and dextran sulfate sodium colitis in rats. "( The Bisphosphonate Pamidronate is an Intestinal Antiinflammatory Agent in Rat and Mouse Experimental Colitis.
González, R; López-Posadas, R; Martínez-Augustin, O; Mascaraque, C; Sánchez de Medina, F; Suárez, MD; Zarzuelo, A, 2016
)
1.1
"Treatment with pamidronate improves the clinical course in children with osteogenesis imperfecta (OI), but theoretically might affect longitudinal growth. "( Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
Glorieux, FH; Plotkin, H; Rauch, F; Zeitlin, L, 2003
)
0.9
"Treatment with pamidronate increased the total BMD as well as that of the metaphysis of the femur but had almost no effect on the BMD of the diaphysis in both control and tail-suspended rats."( Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats.
Fukumoto, S; Fuse, H; Kawahara, H; Kodama, Y; Kurokawa, T; Matsumoto, T; Nakamura, T; Nakayama, K; Sekiguchi, C; Takahashi, H, 1997
)
0.92
"Treatment with pamidronate did not alter the rate of fracture healing, the growth rate, or the appearance of the growth plates."( Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Bishop, NJ; Chabot, G; Glorieux, FH; Lanoue, G; Plotkin, H; Travers, R, 1998
)
0.94
"The treatment with pamidronate reduced pain significantly but did not add noticeably to the costs."( Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate.
Bacchus, L; Gessner, U; Horisberger, B; Koeberle, D; Thuerlimann, B, 2000
)
0.84
"Treatment with pamidronate (Aredia) was successful and reduced the serum calcium to normal values."( [Immobilization hypercalcemia as a complication of polyneuropathy].
Block, F; Brandenburg, VM; Dietrich, CG; Riehl, J, 2000
)
0.65
"Treatment with pamidronate, an inhibitor of osteoclastic bone resorption, given every 2 weeks by i.v."( Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma.
Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimasu, T; Yoshimura, G, 2001
)
2.09
"Treatment with pamidronate resulted in a 7.8% +/- 1.5% increase in mean lumbar spine QCT from 79.4 mg/cm(3) (95% confidence interval [CI], 64-94 mg/cm(3)) to 85.6 mg/cm(3) (95% CI, 70-101 mg/cm(3)) (P = 0.0005) and a 2% +/- 0.9% increase in mean total femoral neck DXA from 0.98 g/cm(2) (95% CI, 0.90 -1.05 g/cm(2)) to 1.0 mg/cm(2) (95% CI, 0.91-1.08 g/cm(2)) (P = 0.02)."( The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.
Bryant, C; De Souza, P; Diamond, TH; Kersley, JH; Lynch, WJ; Smith, A; Winters, J, 2001
)
0.91
"Treatment with pamidronate normalized serum calcium concentration and induced a complete biochemical remission."( Paget's disease with osteolytic lesions: combining medical and surgical treatments.
Bloem, RM; Brumsen, C; Papapoulos, SE, 1992
)
0.62
"Treatment with pamidronate resulted in a higher BMC of the lumbar spine than in the untreated animals, with elevated concentrations of hPTH."( Pamidronate reduces PTH-mediated bone loss in a gene transfer model of hyperparathyroidism in rats.
Dobrolet, NC; Mitlak, BH; Neer, RM; Nussbaum, SR; Rodda, CP; Von Deck, MD, 1991
)
2.06
"Retreatment with pamidronate again resulted in normocalcaemia."( Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.
Allam, BF; Boyce, BF; Boyle, IT; Dryburgh, FJ; Gallacher, SJ; Logue, FC; Ralston, SH, 1990
)
0.83

Toxicity

The effect of oral pamidronate on bone mineral density and its adverse effect profile was investigated by a double-masked placebo-controlled study of 122 patients aged 55-75 years with established vertebral osteoporosis. The incidence of headache in cancer patients with zoledronic acid was significantly lower than that with pamodronate disodium.

ExcerptReferenceRelevance
" The experimental conditions provide a technically simple method which is sensitive enough to examine antiresorptive properties in a healthy animal and to detect adverse effects on the kidney."( Measurement of serum [3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption.
Eitan, Y; Golomb, G; Hoffman, A, 1992
)
0.28
" This potentially serious drug side-effect does not appear to have been reported previously in patients with Paget's disease."( Ototoxicity associated with intravenous bisphosphonate administration.
Mills, DA; Reid, IR; Wattie, DJ, 1995
)
0.29
"In view of previous animal studies showing that pamidronate (Aredia) can cause renal damage, and human data indicating that pamidronate in doses of 60-90 mg is more effective in the control of tumor-induced hypercalcemia than when given at lower doses, we decided to investigate whether pamidronate 90 mg infused over 60 minutes at weekly intervals had any adverse effects on renal function in patients with bone metastases."( Intravenous pamidronate: infusion rate and safety.
Coleman, T; Collinson, M; Ford, JM; Madsen, EL; Tyrrell, CJ, 1994
)
0.92
" APD appears to be a safe drug in patients with underlying renal failure."( Safety of pamidronate in patients with renal failure and hypercalcemia.
Flombaum, CD; Machado, CE, 1996
)
0.7
" Fourteen patients received APD during 3 consecutive days whereas 7 patients have been treated during 2 consecutive days and 2 patients only during 1 day mainly due to adverse events."( Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronate.
Coquerelle, P; Cortet, B; Delcambre, B; Duquesnoy, B; Flipo, RM, 1997
)
0.5
"The effect of oral pamidronate on bone mineral density and its adverse effect profile was investigated by a double-masked placebo-controlled study of 122 patients aged 55-75 years with established vertebral osteoporosis."( Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety.
Blake, GM; Davie, M; Fogelman, I; Gibson, T; Haddaway, M; Ryan, PJ, 2000
)
0.93
"Ophthalmologic adverse effects of bisphosphonate therapy are infrequent and of unclear pathogenesis."( Uveitis, an under-recognized adverse effect of pamidronate. Case report and literature review.
Acquaviva, PC; Bernard, P; Dahan, L; Daumen-Legré, V; Lafforgue, P; Pham, T; Rey, J, 2000
)
0.56
"Case reports from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute), the Food and Drug Administration, the World Health Organization, and the literature were reviewed to determine possible adverse ocular side effects associated with pamidronate disodium."( Scleritis and other ocular side effects associated with pamidronate disodium.
Fraunfelder, FT; Fraunfelder, FW; Jensvold, B, 2003
)
0.74
" The most common adverse events included bone pain, nausea, and fatigue."( Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ, 2003
)
0.56
"Ocular adverse effects of pamidronic acid are rare but well documented."( Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports.
Claes, C; Haverbeke, G; Pertile, G; Zeyen, T, 2003
)
0.56
"To assess the effectiveness of pretreatment with ibuprofen or acetaminophen compared with no pretreatment in decreasing adverse events in children and adolescents receiving the first and second series of pamidronate therapy; and to compare the effectiveness of ibuprofen versus acetaminophen for prevention of adverse events associated with pamidronate infusion."( Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents.
Bates, CM; Batisky, DL; Hayes, JR; Mahan, JD; Nahata, MC; Robinson, RE, 2004
)
0.74
" Adverse drug events secondary to pamidronate infusion and subsequent drug therapies received were documented."( Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents.
Bates, CM; Batisky, DL; Hayes, JR; Mahan, JD; Nahata, MC; Robinson, RE, 2004
)
0.83
"Pretreatment with ibuprofen or acetaminophen appears to decrease the occurrence of adverse events from pamidronate therapy."( Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents.
Bates, CM; Batisky, DL; Hayes, JR; Mahan, JD; Nahata, MC; Robinson, RE, 2004
)
0.77
" Regular Z 4 mg infusions appear to be safe in these patients, with routine monitoring of serum creatinine."( Bisphosphonate infusions: patient preference, safety and clinic use.
Chern, B; Copeman, M; De Abreu Lourenco, R; Joseph, D; Joshua, D; Lowe, S; Lynch, K; Pittman, K; Richardson, G; Schou, M, 2004
)
0.32
" The nitrogen-containing bisphosphonate pamidronate was significantly more toxic on a panel of eight neuroblastoma cell lines than the non-nitrogen-containing bisphosphonates, clodronate and tiludronate."( In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Boos, J; Lanvers-Kaminsky, C; Vorotnjak, M, 2004
)
0.59
" The safety profiles among all intravenous bisphosphonates were similar; patients treated with intravenous bisphosphonates reported notably less bone pain but a higher incidence of mild to moderate transient infusion-related adverse events (eg, nausea, vomiting, myalgia, and anorexia) compared with placebo."( Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Gordon, DH, 2005
)
0.33
" Current reports have focused on therapy-resistant osteonecrosis of the jaws as a possible side effect of bisphosphonates."( [Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates].
Eufinger, H; Hoefert, S, 2005
)
0.33
" The presentation of these cases is intended to call attention to this clinically important side effect of bisphosphonate medication."( [Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates].
Eufinger, H; Hoefert, S, 2005
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" As clinical indications of intravenous bisphosphonates continue to expand, prescribing clinicians should be familiar with these possible adverse effects and discuss them with patients before commencing or continuing on therapy."( Management of the adverse effects associated with intravenous bisphosphonates.
Stiff, PJ; Tanvetyanon, T, 2006
)
0.33
" As a conclusion, pamidronate administration at the dose of 90 mg/day/month was safe for Japanese breast cancer patients with bone metastasis."( [Retrospective evaluation of the safety of pamidronate administration at the dose of 90 mg/day/month in Japanese breast cancer patients with bone metastasis].
Aogi, K; Ohsumi, S; Okita, A; Taira, N; Takashima, S, 2006
)
0.93
" Patterns of nephrotoxicity described with these agents include toxic acute tubular necrosis and collapsing focal segmental glomerulosclerosis, respectively."( Bisphosphonate nephrotoxicity.
Markowitz, GS; Perazella, MA, 2008
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Outcomes of adverse events were defined as inflammatory conditions of the jaw, including osteonecrosis; major jaw surgery for necrotic or inflammatory conditions; or jaw surgeries for malignancies."( Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.
Hay, JW; Jeffcoat, MK; Seal, B; Skrepnek, GH; Tangirala, M; Watts, NB,
)
0.13
" In conclusion, the present study shows that the use of ZOL in the dosage and period studied was safe and efficient to promote a clinical and densitometric improvement, similarly to PAM."( Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
Barros, ER; de Oliveira, TP; Lazaretti-Castro, M; Saraiva, GL, 2012
)
0.61
" Adverse events were measured by collecting calcium levels before and after infusions."( Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings.
DeHaai, K; Kreikemeier, RM; Lutz, RE; Rush, ET, 2012
)
0.6
" Apart from transient fever and moderate hypophosphatemia, no side-effect of bisphosphonate treatment was observed."( Efficacy and safety of pamidronate in children with vitamin D intoxication.
Aycan, Z; Aydın, M; Can Yılmaz, G; Çetinkaya, S; Gündüz, S; Kara, C, 2016
)
0.74
"Pamidronate is efficient and safe for the treatment of VDI in children."( Efficacy and safety of pamidronate in children with vitamin D intoxication.
Aycan, Z; Aydın, M; Can Yılmaz, G; Çetinkaya, S; Gündüz, S; Kara, C, 2016
)
2.19
"Cardiotoxicity is the major side effect of doxorubicin."( Pamidronate Attenuates Oxidative Stress and Energetic Metabolism Changes but Worsens Functional Outcomes in Acute Doxorubicin-Induced Cardiotoxicity in Rats.
Alegre, PH; Antonio, L; Azevedo, PS; Bergamasco, CM; Carvalho, PB; Fernandes, AA; Gonçalves, AF; Minicucci, MF; Modesto, PN; Paiva, SA; Polegato, BF; Roscani, MG; Zornoff, M, 2016
)
1.88
" BP treatment was safe and caused no obvious impairment on children's linear growth."( EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
Jiang, Y; Li, M; Meng, X; Wang, O; Wang, Y; Xia, W; Xing, X, 2019
)
0.51
"Bone metastatic disease may lead to serious adverse events in patients with cancer."( Adverse events associated with bone-directed therapies in patients with cancer.
Hu, MI; Jara, MA; Varghese, J, 2022
)
0.72
" Authors reviewed self-created questionnaires, which asked patients for symptoms alleviation, adverse drug reactions frequency and degree of severity and daily activities self-reliance."( Patient-reported effectiveness and safety of Pamidronate in NSAIDs-refractory chronic recurrent multifocal osteomyelitis in children.
Juszczak, B; Sułko, J, 2022
)
0.98
"This study demonstrates that Pam is effective and safe for treating PTHRH, while ensuring close laboratory monitoring of calcium and phosphorus metabolism."( Efficacy and Safety of Intravenous Pamidronate for Parathyroid Hormone-dependent Hypercalcemia in Hospitalized Patients.
Barzilay-Yoseph, L; Klein, N; Ramaty, E; Rosenblum, RC; Rotman-Pikielny, P; Twito, O, 2021
)
0.9
" The incidence of febrile adverse reactions from incardronate was significantly lower than pamidronate disodium (OR =0."( Side effects of incardronate disodium compared to pamidronate disodium in the treatment of bone metastasis pain: a systematic review and meta-analysis.
He, L; Meng, R; Tang, Z; Wang, Y, 2021
)
1.1
" However, incardronate had fewer adverse reactions than pamidronate disodium."( Side effects of incardronate disodium compared to pamidronate disodium in the treatment of bone metastasis pain: a systematic review and meta-analysis.
He, L; Meng, R; Tang, Z; Wang, Y, 2021
)
1.12
"Atypical femur fracture (AFF) is a rare but catastrophic adverse event first reported in the long-term use of alendronate, one of the most commonly used drugs for osteoporosis currently."( Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.
Chen, Y; Huang, Y; Xiao, Y, 2023
)
0.91

Pharmacokinetics

Pamidronate has a toxic bone BP threshold of 0.0. The initial plasma half-life of pamidrone was short (42 +/- 27 min) and the apparent total plasma clearance was high (471 +/- 298 ml/min)

ExcerptReferenceRelevance
" Despite the known effects of APD on bone turnover rates and osteoclast activity, the dose appeared to have no significant influence on the biological half-life of APD in bone which was found to be 90-140 days."( The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse.
Bennett, R; Daley-Yates, PT; Hoggarth, CR, 1991
)
0.55
" The initial plasma half-life of pamidronate was short (42 +/- 27 min) and the apparent total plasma clearance was high (471 +/- 298 ml/min)."( The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases.
Coleman, RE; Daley-Yates, PT; Dodwell, DJ; Howell, A; Pongchaidecha, M, 1991
)
0.84
" We conclude that pharmacokinetic studies of diphosphonates cannot be conducted reliably with 99mTc-labelled compounds."( A comparison of the pharmacokinetics of 14C-labelled APD and 99mTc-labelled APD in the mouse.
Bennett, R; Daley-Yates, PT, 1988
)
0.27
" The pharmacokinetic parameters, including total clearance, renal clearance, and nonrenal clearance, were found to be not significantly affected by the rate of infusion."( Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats.
Daley-Yates, PT; Pongchaidecha, M,
)
0.37
" Consequently, main pharmacokinetic parameters (AUC, CL, and V(ss)) were influenced by the mode of drug administration, precluding accurate determination of bioavailability from AUC values."( Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination.
Ezra, A; Golomb, G; Hoffman, A; Stepensky, D; Van Gelder, JM, 2001
)
0.31
" The design of therapeutic regimens with bisphosphonates is mainly based on pharmacodynamic (PD) information."( A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis.
Cremers, S; den, HJ; Hamdy, N; Papapoulos, S; Sparidans, R; Vermeij, P, 2002
)
0.54
" The assay was applied to the analysis of samples from a pharmacokinetic study."( High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans.
Kwon, KI; Yun, MH, 2006
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

Pamidronate (3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid) combined with mitomycin C (MMC) on bone metastasis of breast cancer using an animal model.

ExcerptReferenceRelevance
" In the present study we have evaluated the therapeutic efficacy of pamidronate (3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid) combined with mitomycin C (MMC) on bone metastasis of breast cancer using an animal model."( Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model.
Enomoto, K; Ikeda, T; Ishii, S; Kitajima, M; Tamura, H; Wada, N, 1996
)
0.84
"Nocturnal infusion of 5-fluorouracil (5-FU) combined with pamidronate was performed in a 62-year-old male gastric cancer patient with multiple bone metastasis."( [A case of gastric cancer with multiple bone metastasis treated by nocturnal 5-fluorouracil infusion combined with pamidronate].
Fukano, S; Furuya, Y; Kinugasa, T; Kohno, N; Maekawa, Y; Sekimoto, K; Toyokawa, A, 1998
)
0.75
" Bonin, as a safe and effective Bisphosphonates preparation, could relieve bone pain in multiple myeloma more effectively when combined with chemotherapy."( [Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma].
Chen, SL; Leng, Y; Shi, HZ, 2002
)
0.69
"To study the effect on the bone mineral density of a bisphosphonate (pamidronate) given intravenously, in combination with oral calcium and vitamin D supplements, compared with oral calcium and vitamin D supplements alone."( A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease.
Bartram, SA; Francis, RM; Peaston, RT; Rawlings, DJ; Thompson, NP, 2003
)
0.77
"Seventy-four patients with Crohn's disease and low bone mineral density at the lumbar spine and/or hip were randomized to receive either a daily dose of 500 mg of calcium with 400 IU of vitamin D alone or in combination with four three-monthly infusions of 30 mg of intravenous pamidronate over the course of 12 months."( A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease.
Bartram, SA; Francis, RM; Peaston, RT; Rawlings, DJ; Thompson, NP, 2003
)
0.71
"We conclude that intravenous pamidronate in combination with calcium and vitamin D is a well tolerated strategy for treating Crohn's disease associated osteopenia and osteoporosis."( Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
Deley, M; Hommes, DW; Stokkers, PC; Van Der Spek, M; Van Deventer, SJ; Verberne, HJ, 2006
)
1
" In the present study, we demonstrated the effects of vitamin K(2) alone or in combination with pamidronate in an arterial calcification model induced using inorganic phosphate in cultured bovine aortic smooth muscle cells (BASMCs)."( Treatment with vitamin k(2) combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells.
Saito, E; Sato, F; Seyama, Y; Sugitani, H; Wachi, H, 2007
)
0.56
"Calcium deposition assay and von Kossa staining showed that calcification could be inhibited in a dose-dependent manner by treatment with vitamin K(2) alone, and that its inhibitory effect was enhanced when combined with pamidronate."( Treatment with vitamin k(2) combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells.
Saito, E; Sato, F; Seyama, Y; Sugitani, H; Wachi, H, 2007
)
0.52
"Taken together, our study suggests that vitamin K(2) in combination with pamidronate synergistically inhibits arterial calcification via the increased expression of tropoelastin, which would be a useful marker for developing effective therapeutic or prophylactic agents for arterial calcification."( Treatment with vitamin k(2) combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells.
Saito, E; Sato, F; Seyama, Y; Sugitani, H; Wachi, H, 2007
)
0.57
" In conclusion, RT combined with BMA was found to be more effective than BMA alone for the treatment of osteolytic bone metastasis, which thereby improves the prognosis."( Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer.
Kajima, M; Makita, C; Manabe, Y; Matsuo, M; Matsuyama, K; Tanaka, H, 2020
)
0.56
"This study investigates the effect of tannic acid (TA) combined with pamidronate (PAM) on a human osteoblast cell line."( The Effects of Polyphenol, Tannic Acid, or Tannic Acid in Combination with Pamidronate on Human Osteoblast Cell Line Metabolism.
Abdullah, H; Hapidin, H; Hashim, NM; Kasiram, MZ, 2022
)
1.19
"To explore the effects of pamidronate disodium combined with calcium on BMD values and the severity of pain in elderly patients with osteoporosis based on the mobile terminal platform for the Internet of Things."( Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things.
Bai, Z; Guo, P; Kang, M; Wang, D; Wang, J, 2022
)
1.41
"The treatment of pamidronate disodium combined with calcium based on the mobile terminal platform for the Internet of Things can reduce the severity of pain in elderly patients with osteoporosis and improve the BMD, which has a generalization value."( Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things.
Bai, Z; Guo, P; Kang, M; Wang, D; Wang, J, 2022
)
1.45

Bioavailability

The pharmacokinetics and bioavailability of pamidronate were assessed in patients with breast cancer. 6 subjects received the drug intravenously and 7 orally.

ExcerptReferenceRelevance
"The pharmacokinetics and bioavailability of pamidronate were assessed in patients with breast cancer, 6 subjects received the drug intravenously and 7 orally."( The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases.
Coleman, RE; Daley-Yates, PT; Dodwell, DJ; Howell, A; Pongchaidecha, M, 1991
)
0.82
" A maximal cefoxitin bioavailability of 85 +/- 10% was achieved by infusion with 4% w/v of APD, compared with 14 +/- 12% without APD."( 3-Amino-1-hydroxypropylidene-1,1-diphosphonate (APD): a novel enhancer of rectal cefoxitin absorption in rats.
Breimer, DD; de Boer, AG; van Hoogdalem, EJ; Wackwitz, AT, 1989
)
0.28
"To validate our hypothesis that a bisphosphonate (BP) having a nitrogen-containing heterocyclic ring on the side chain, and with no hydroxyl on the geminal carbon would possess increased activity, and better oral bioavailability due to enhanced solubility of its calcium complexes/salts and weaker Ca chelating properties."( Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.
Alferiev, IS; Breuer, E; Cohen, H; Ezra, A; Golomb, G; Hägele, G; Hoffman, A; Mönkkönen, J; Ornoy, A; Patlas, N; Pinto, T; Sagi, H; Seibel, MJ; Solomon, V; Stepensky, D, 1999
)
0.3
" Although newer bisphosphonates are more potent, oral bioavailability remains < 1%."( Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000
)
0.31
" Low oral bioavailability is the most likely reason for this difference."( Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000
)
0.31
" Consequently, main pharmacokinetic parameters (AUC, CL, and V(ss)) were influenced by the mode of drug administration, precluding accurate determination of bioavailability from AUC values."( Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination.
Ezra, A; Golomb, G; Hoffman, A; Stepensky, D; Van Gelder, JM, 2001
)
0.31
"Menkes disease is a severe multisystem disorder due to defective bioavailability and transport of copper at the cellular level."( Pamidronate treatment improves bone mineral density in children with Menkes disease.
Boneh, A; Kanumakala, S; Zacharin, M, 2002
)
1.76
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" In this work, disodium pamidronate was complexed with phospholipon 90G for the enhancement of permeability and to investigate the phospholipon 90G-tagged pamidronate complex-loaded SNEDDS for oral delivery with promises of enhanced bioavailability and anti-osteoporotic activity."( Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis.
Ahmad, FJ; Alam, MI; Ansari, MD; Aqil, M; Solanki, P; Sultana, Y, 2023
)
1.47

Dosage Studied

Intravenous drip of pamidronate was given at the dose of 30 - 60 mg per day for 2 - 3 weeks with a total dosage of 90 - 270 (168 +/- 84) mg to 5 patients with Paget's disease of bone. Review of the published literature suggests that a clinically relevant dose-response relationship exists in the dose range 30-60 mg. Most hypercalcemic patients will achieve normocalcemia with a dose of 60 mg pamodronate or more.

ExcerptRelevanceReference
" There was no dose-response relationship between the dose of APD given and the percentage reduction in ALP and HYPRO at 6 months."( Bisphosphonate space measurement in Paget's disease of bone treated with APD.
Evans, AJ; Hosking, DJ; Marshall, DH; Perkins, AC; Stone, MD; Wastie, ML, 1992
)
0.28
" Pharmacokinetic data and clinical trials are reviewed, as well as adverse effects and dosage guidelines."( Pamidronate.
Kellihan, MJ; Mangino, PD, 1992
)
1.73
" However, with both modes of administration, it was evident that after equivalent dosing peroral and parenteral studies yielded similar results."( Reproduction toxicity studies with pamidronate.
Bentley, P; Fritz, H; Graepel, P; Miyamoto, M; Slater, SR, 1992
)
0.56
" Four of the six patients in group 1A achieved normal ALP, whereas ALP remained at an increased level in all of the 10 patients in group 2 whose pretreatment ALP was greater than 1000 U/l, suggesting that a dose-response effect exists."( Clinical experience with pamidronate in the treatment of Paget's disease of bone.
Boyce, BF; Boyle, IT; Gallacher, SJ; Jenkins, A; Patel, U; Ralston, SH, 1991
)
0.58
" The author discusses the administration, dosage and side effects, and results of current studies."( Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
Coleman, RE, 1991
)
0.28
"A 10-year-old boy with leukaemia-associated hypercalcaemia was treated with aminohydroxypropylidene biphosphonate (AHPrBP previously APD) in a total dosage of 60 mg over 5 days, when the condition failed to respond to rehydration and frusemide and no sustained effect was produced by haemodialysis with a calcium (Ca)-free dialysate."( Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate.
Boudailliez, BR; Kremp, O; Pautard, BJ; Piussan, CX; Sebert, JL, 1990
)
0.28
" In order to establish a dose-response in humans, patients were divided into four groups receiving 30 mg, 45 mg, 60 mg, or 90 mg, respectively, as a 24-hour infusion."( Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
Burckhardt, P; Jacquet, AF; Jaeger, P; Thiébaud, D, 1988
)
0.27
" Serum calcium and 1,25-dihydroxyvitamin D levels remained normal at all dosage levels."( Inhibition of bone matrix apposition by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (AHPrBP) in the mouse.
Garba, MT; Hott, M; Marie, PJ, 1985
)
0.27
" In prostate cancer patients, the same regimens of pamidronate produced reductions in bone pain, but no dose-response relationship was apparent."( Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer.
Glover, D; Grabelsky, S; Harvey, H; Lipton, A; Macerata, R; Seaman, J; Zelenakas, K, 1994
)
1.98
" Review of the published literature suggests that a clinically relevant dose-response relationship exists in the dose range 30-60 mg; most hypercalcemic patients will achieve normocalcemia with a dose of 60 mg pamidronate or more."( Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects?
Thürlimann, B, 1994
)
0.7
" Although there was no significant difference in response between the lower dosage groups, there was a greater response in patients treated with a higher dose of APD."( Single-day intravenous pamidronate in Paget's disease.
Clifton-Bligh, P; Forman, L; Hooper, MJ; Lang, FV; Marel, GM; McDowall, D; Tancred, J, 1994
)
0.6
"Our data demonstrate a dose-response relationship for pamidronate in TIH over an efficient hypocalcaemic dose range, at least in patients with an elevated tubular calcium reabsorption, which helps to resolve conflicting data in the literature."( Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body, JJ; Dumon, JC, 1994
)
0.77
"Bisphosphonates are clinically useful for the treatment of bone disorders; however, there is some controversy concerning the extent to which the design of the dosage regimen influences the efficacy of these drugs."( Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats.
Daley-Yates, PT; Pongchaidecha, M,
)
0.37
" We have evaluated the effectiveness of three dosage regimes of aminohydroxypropylidene bisphosphonate (pamidronate) in 15 patients with extensive Paget's disease who had become refractory to conventional therapy."( Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
Gunasekera, RD; Wimalawansa, SJ, 1993
)
1.94
"To determine the efficacy, dose-response relationship, and safety of 30, 60, and 90 mg of a single intravenous dose of an aminobisphosphonate, pamidronate (APD), for the treatment of moderate to severe hypercalcemia of malignancy."( Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Chapman, R; Gagel, RF; Henderson, IC; Mallette, LE; Nussbaum, SR; Vandepol, CJ; Younger, J; Zubler, MA, 1993
)
0.76
" A dose-response relationship for normalization of corrected serum calcium was seen after pamidronate administration."( Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Chapman, R; Gagel, RF; Henderson, IC; Mallette, LE; Nussbaum, SR; Vandepol, CJ; Younger, J; Zubler, MA, 1993
)
0.78
" Compared with gallium nitrate, pamidronate offers a more convenient dosing regimen, is less frequently associated with nephrotoxicity, and is less expensive."( Update on the medical treatment of hypercalcemia of malignancy.
Hall, TG; Schaiff, RA, 1993
)
0.57
" The 30 patients with clinical, laboratory test, and/or roentgenographic evidence of active Paget's disease were given intravenous pamidronate in a dosage of 60 or 120 mg."( Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate.
Bon, E; Cantagrel, A; Constantin, A; Laroche, M; Mazieres, B; Moulinier, L; Ramonjisoa, M,
)
0.57
" Patients received, on average, 30 mg less pamidronate than that given in the manufacturer's dosing schedule."( An audit of the management of malignant hypercalcaemia.
Dodwell, DJ; Gerrard, GE; Overend, MA; Vail, A; Watters, J, 1996
)
0.56
"An intravenous dosage schedule using pamidronate disodium, based on biochemical severity, was used to treat 71 patients with Paget's disease who had no previous bisphosphonate treatment."( Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
Bhagat, CI; Gutteridge, DH; Kent, GN; Nicholson, GC; Price, RI; Prince, RL; Retallack, RW; Stewart, GO; Stuckey, BG; Thompson, RI; Ward, LC, 1996
)
0.78
" In osteoporotic syndromes, APD is prescribed at a lower dosage (200 mg/day) and currently calcium or vitamin D are also systematically added."( [Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients].
Castelli, G; Kerzberg, EM; Lloret, AP; Roldan, EJ, 1996
)
0.59
" Older and newer-generation bisphosphonates have an inhibitory effect on calcium oxalate urolithiasis that is demonstrable at relatively infrequent dosing intervals in vivo."( Inhibition of calcium oxalate urolithiasis in a rat model of lithogenesis using bisphosphonates.
Gupta, M; Smith, AD; Tuncay, OL; Valderrama, E, 1997
)
0.3
" Rats were dosed concomitantly with indomethacin (40 mg/kg, subcutaneously) and an amino or pyridinyl bisphosphonate (orally at."( Nonclinical model for assessing gastric effects of bisphosphonates.
Berman, SK; Blank, MA; Ems, BL; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN, 1997
)
0.3
" Efficacy on laboratory parameters was greater in the higher dosage group."( Pamidronate infusions for the treatment of Paget's disease of bone.
Ahmed, I; Bon, E; Cantagrel, A; Laroche, M; Mazieres, B; Moulinier, L, 1996
)
1.74
"We have performed a 2-year prospective double-masked study to determine whether the bisphosphonate pamidronate can prevent bone loss in postmenopausal women and its optimal dosage regimen."( Role of oral pamidronate in preventing bone loss in postmenopausal women.
Garland, SW; Lees, B; Ross, D; Stevenson, JC; Walton, C; Whitehead, MI, 1996
)
0.88
" We investigated the value of two multivariate data transformations, the cumulative log ratio and the continuation log ratio, in the analysis of an experimental study of the dose-response effect of a drug treatment on bone mineralization."( Analysis of compositional bone density data using log ratio transformations.
Bracci, PM; Bull, SB; Grynpas, MD, 1998
)
0.3
" Study 1 is a retrospective study of 20 patients with moderate to severe disease who were treated with intravenous (iv) pamidronate (221 +/- 18 mg [SEM]; range 60-360 mg), and after biochemical remission and relapse were retreated with generally larger iv dosage (293 +/- 28 mg; range 180-600 mg)."( Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another.
Bhagat, CI; Criddle, A; Faulkner, DL; Gan, SK; Geelhoed, E; Gutteridge, DH; Kent, GN; Price, RI; Prince, RL; Retallack, RW; Stewart, GO; Stuckey, BG; Vasikaran, S; Ward, LC; Will, RK, 1999
)
0.51
"6 mg/kg of MDL 103,323 did not further increase BMD or bone strength, indicating a bell-shaped dose-response curve."( The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats.
Ammann, P; Bonjour, JP; Bourrin, S; Brunner, F; Meyer, JM; Rizzoli, R, 1999
)
0.3
" Oral dosing should not be substituted for intravenous administration in the treatment of malignant osteolysis."( Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000
)
0.31
"This study evaluated the dose-response relation for zoledronic acid, a new generation high potency bisphosphonate, given as a 5-minute infusion in patients with malignant osteolytic disease."( Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Berenson, JR; Coleman, RE; Dreicer, R; Howell, A; Kuross, SA; Lipton, A; Morley, W; Porter, L; Rosen, LS; Seaman, JJ, 2001
)
0.31
" Dosage groups were well matched at baseline for demographics, disease activity, and functional indices."( A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
Aaron, SL; Chiu, P; Davis, P; Fitzgerald, AA; Homik, J; Jhangri, GS; LeClercq, S; Maksymowych, WP; Russell, AS; Sholter, D; Skeith, KJ; Yan, A, 2002
)
0.54
" Four of the five patients were able to reduce the dosage of their usual medications."( Pamidronate treatment in SAPHO syndrome.
Guignard, S; Job-Deslandre, C; Kahan, A; Sayag-Boukris, V, 2002
)
1.76
" Drug/placebo was administered intravenously daily for 3 consecutive days, and this 3-day dosing session was repeated at 3-month intervals for one year."( Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial.
Bachrach, SJ; Harcke, HT; Henderson, RC; Kecskemethy, HH; Lark, RK; Miller, F, 2002
)
0.31
" The first dosing with pamidronate caused a transient drop in serum calcium that was asymptomatic and not treated."( Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial.
Bachrach, SJ; Harcke, HT; Henderson, RC; Kecskemethy, HH; Lark, RK; Miller, F, 2002
)
0.63
" Medications or other diseases affecting bone metabolism and chemotherapy within 28 days of dosing were exclusion criteria."( A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Bekker, PJ; Body, JJ; Coleman, RE; Dunstan, CR; Facon, T; Fermand, JP; Geurs, F; Greipp, P; Harousseau, JL; Holloway, D; Lipton, A; Mariette, X; Martin, SW; Nakanishi, A; Williams, CD, 2003
)
0.32
" Hypercalcemia and a history of nephrocalcinosis had prevented appropriate dosing of calcium prior to and during the first months of her hospital stay."( Pamidronate in a girl with chronic renal insufficiency dependent on parenteral nutrition.
Chesney, RW; Duke, JL; Frizzell, NK; Hak, EB; Jones, DP, 2003
)
1.76
"Intravenous drip of pamidronate was given at the dose of 30 - 60 mg per day for 2 - 3 weeks with a total dosage of 90 - 270 (168 +/- 84) mg to 5 patients with Paget's disease of bone, 2 males and 3 females, aged 27 - 74 (61 on average) with the course of disease of 4 - 48 years (24 years on average), all of them having multiple bone lesions, 2 being in grade 4 of pain assessment and bedridden and 3 being in grade 3 with impaired mobility."( [Prospective study of pamidronate disodium in treatment of Paget's disease of bone].
Fu, Y; Jiang, Y; Li, M; Meng, XW; Wang, O; Xia, WB; Xing, XP; Zhang, ZL; Zhou, XY, 2003
)
0.96
" The effect of intravenous infusions of bisphosphonates are, to a large extent, similar to equivalent intramuscular administrations, but doses and dosing intervals represent the critical issues."( Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
Adami, S; Crepaldi, G; Filipponi, P; Sartori, L, 2003
)
0.32
" The standard dosing regime for pamidronate was 1 mg/kg to a maximum of 30 mg, administered daily for three consecutive days, repeated 3-monthly as required."( Pamidronate in the treatment of childhood SAPHO syndrome.
Beresford, MW; Cleary, AG; Davidson, JE; Kerrison, C, 2004
)
2.05
"In all five patients, ranging from 47 to 68 years of age, we used continuous pamidronate infusions perioperatively at a dosage of 120 mg in the first 12 h and subsequent reduction to 75-60-30-15 mg/12 h over a period of 10-14 days."( Amino-bisphosphonates in heterotopic ossification: first experience in five consecutive cases.
Christ-Crain, M; Dick, W; Haas, H; Mueller, B; Schuetz, P, 2005
)
0.56
" Since the therapeutic window of amino-bisphosphonates has not yet been defined and the minimal necessary doses for preventing new HO are unknown, further studies are encouraged to confirm our findings and to identify the necessary dosage and duration of treatment and to pinpoint, which patients will benefit most from this treatment."( Amino-bisphosphonates in heterotopic ossification: first experience in five consecutive cases.
Christ-Crain, M; Dick, W; Haas, H; Mueller, B; Schuetz, P, 2005
)
0.33
" We also set out to investigate local delivery to assess whether systemic exposure could be eliminated, due to concerns of bisphosphonate dosing of non-target organs."( A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair.
Amanat, N; Bilston, LE; Brown, R; Little, DG, 2005
)
0.63
"Combined dosing of pamidronate and 1,24(OH)2D2 may have therapeutic value for the treatment of multiple myeloma, prostate and breast cancers."( Pamidronate and 1,24(S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells.
Knutson, JC; Strugnell, SA; Wigington, DP,
)
1.9
" Two patients had early death (one from massive cerebral ischemic stroke, the other from dementia and progressive renal failure), one patient progressed during Thali-Dexa (thalidomide 200mg) and was rescued with chemotherapy, two patients required increasing thalidomide dosage (to 200 and 400mg, respectively) because of progressive disease, three patients had stable disease remission lasting from 4m+ to 16m+."( Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma.
Bemardeschi, P; Dentico, P; Fiorentini, G; Giustarini, G; Rossi, S; Turano, E, 2003
)
0.32
" Our study suggests that pamidronate decreases bone turnover and is effective in preventing the course of bone loss after LT, however the efficacy, at the dosage regimen employed and in a follow-up of 12 months, appears to be limited to trabecular bone, with no effect on the cortical structure of the femur."( Pamidronate and osteoporosis prevention in liver transplant recipients.
Fiore, CE; Giostra, E; Mentha, G; Pennisi, P; Rizzoli, R; Trombetti, A, 2007
)
2.09
"To describe the biochemical and adverse effects of a convenient single 90 mg pamidronate dose in patients with acute spinal cord injury (SCI) and compare these effects with those observed in a previous similar study using a 30 mg/d x 3-day pamidronate dosing regimen."( Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury.
Liu, K; Mechanick, JI; Nierman, DM; Stein, A, 2006
)
0.84
"Responses of biochemical markers of bone resorption (N-telopeptide and 24-hour urinary calcium excretion) to pamidronate 90 mg were consistent with an antiresorptive effect, although less than that observed with a 30 mg/d x 3-day pamidronate dosing regimen."( Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury.
Liu, K; Mechanick, JI; Nierman, DM; Stein, A, 2006
)
0.82
"Single-dose pamidronate 90 mg is effective at reducing biochemical markers of bone hyperresorption in patients with acute SCI but is associated with a greater incidence of fever compared with a 30 mg/d x 3-day dosing regimen."( Effect of a convenient single 90-mg pamidronate dose on biochemical markers of bone metabolism in patients with acute spinal cord injury.
Liu, K; Mechanick, JI; Nierman, DM; Stein, A, 2006
)
0.99
" Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure."( Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E, 2007
)
0.34
" Antifracture efficacy has been demonstrated for at least three nitrogen-containing bisphosphonates in oral formulations that are designed to be administered in weekly or monthly dosing regimens."( Use of intravenous bisphosphonates in osteoporosis.
Armamento-Villareal, R; Civitelli, R; Napoli, N, 2007
)
0.34
"Metaphyseal bands, which we call zebra lines, were observed with band intervals that were dependent on the age of the patient, the rate of growth, and the dosing regimen."( Zebra lines of pamidronate therapy in children.
Al Muderis, M; Azzopardi, T; Cundy, P, 2007
)
0.69
" Intravenous pamidronate is efficacious and has long been available, but its use is hindered by an impractical recommended dosing regimen of 30 mg IV over 4 h for three consecutive days."( A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson, A, 2008
)
0.72
" Bisphosphonates restore normal bone turnover and relieve bone pain, but oral formulations may be limited by complicated dosing regimens and poor gastrointestinal absorption."( A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson, A, 2008
)
0.35
"Five patients with CRMO, all of whom had ongoing pain and loss of function despite conventional treatment with non-steroidal anti-inflammatory agents, were treated with pamidronate (1 mg/kg/dose with a dosing frequency of 2 to 4 monthly for a total treatment duration of 12 to 42 months)."( Bisphosphonate treatment in chronic recurrent multifocal osteomyelitis.
Allen, RC; Simm, PJ; Zacharin, MR, 2008
)
0.54
" In patients with PMO, zoledronate and pamidronate are associated with significantly less nephrotoxicity, which undoubtedly relates to the lower doses and longer dosing intervals employed for this indication."( Bisphosphonate nephrotoxicity.
Markowitz, GS; Perazella, MA, 2008
)
0.62
" Six BPs are currently approved by the US Food and Drug Administration (FDA) for the treatment of Paget disease, and each has unique characteristics, such as response rates and requirements for dosage and administration, relevant to clinical outcome."( Paget disease of bone: therapeutic options.
Silverman, SL, 2008
)
0.35
" Immunosuppression was cyclosporine and prednisolone, with no difference in dosing between the 2 groups."( Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.
Altmann, P; Andrews, C; Banks, LM; Cockwell, P; Cunningham, J; Dudley, C; Hall-Craggs, M; Noonan, K; Pattison, J; Sweny, P; Walsh, SB; Wilkie, M; Yaqoob, MM, 2009
)
0.76
"For patients with HCM who do not achieve a response from bisphosphonates, or for those who need repeated dosing more often than expected, changing to a different drug class could be an alternative."( A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
Linneman, T; McMahan, J, 2009
)
0.35
"Administration of biphosphonates in patients with renal failure requires a dosage adjustment."( [Effect of pamidronate infusion time on renal function in patients with multiple myeloma].
Barreda, C; Moleón, M; Navarro, A; Pastor, J; Román, E; Sierra, F,
)
0.52
"Patients with severe osteoporosis receiving APD infusions had a high rate of fractures without significant changes in bone mass or in bone markers; nevertheless, such a therapeutic regimen showed a good renal safety profile, suggesting that APD at this dosage is safe but ineffective for treating severe osteoporosis."( Effects of intravenous pamidronate on renal function, bone mineral metabolism and bone mass in patients with severe osteoporosis.
Gifre, L; Guañabens, N; Hernández, MV; Monegal, A; Muxi, A; Peris, P; Reyes, R, 2010
)
0.67
" Other aspects of BP therapy that require further study include the optimization of dosing regimens for single agents and combinations in various clinical settings and the identification of prognostic factors that predict treatment outcomes."( Bisphosphonates as anticancer therapy for early breast cancer.
Jahanzeb, M; Mahtani, R, 2010
)
0.36
" Finally, we approach the future of BP use in MM in the context of other bone-targeted agents, evaluating ongoing clinical trials addressing alternate dosing and schedules of BP administration in MM patients."( The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
Pozzi, S; Raje, N, 2011
)
0.37
" However, clinical efficacy and optimal dosing in non-OI patients has not been established."( Treatment of symptomatic osteoporosis in children: a comparison of two pamidronate dosage regimens.
Huang, C; Martinez-Soto, T; Pacaud, D; Stephure, D; Trussell, R, 2011
)
0.6
" We show a theoretical example of how alternative dosing might reduce the ratio and therefore decrease the chance of formation of a stress riser."( Fracture after bisphosphonate treatment in children with cerebral palsy: the role of stress risers.
Bachrach, SJ; Grissom, LE; Harcke, HT; Kecskemethy, HH; Stevenson, KL, 2012
)
0.38
") dosing or periodically with oral bisphosphonates is advised."( Renal complications from bisphosphonate treatment.
Hirschberg, R, 2012
)
0.38
"Despite substantial variability in individual risk of skeletal complications, patients with metastatic bone disease are treated with bisphosphonates at the same dose and dosing interval."( Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer.
Amir, E; Carlsson, L; Clemons, M; Dranitsaris, G; Freedman, O; Laupacis, A; Tannock, IF; Tomlinson, G, 2013
)
0.6
" In conclusion, the present study shows that the use of ZOL in the dosage and period studied was safe and efficient to promote a clinical and densitometric improvement, similarly to PAM."( Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
Barros, ER; de Oliveira, TP; Lazaretti-Castro, M; Saraiva, GL, 2012
)
0.61
" They differed markedly in study type, pharmacological agent used, dosing regimen, disease, aetiology/stage/location, concurrent off-loading regimen, outcomes and, follow-up."( A Surgeon's guide to advances in the pharmacological management of acute Charcot neuroarthropathy.
Afsie, S; Al-Nammari, SS; Timothy, T, 2013
)
0.39
" These data provide the basis for less frequent dosing of aBPs."( Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
Anderson, KC; Ghobrial, IM; Laubach, JP; Munshi, NC; Nemani, N; Patel, CG; Raje, NS; Richardson, PG; Santo, L; Schlossman, RL; Scullen, TA; Yee, AJ, 2014
)
0.4
" Pamidronate disodium was diluted in isotonic saline and administered by slow ravenous infusion over 3 hours in a dosage 1 mg/kg/day for 3 consecutive days 3 monthly for 2 years."( Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Atta, I; Ibrahim, M; Iqbal, F; Khan, YN; Lone, SW; Raza, J, 2014
)
1.63
" These traceable BPs were dosed to Wistar rats in models of normal growth and closed fracture repair."( PTH(1-34) Treatment Increases Bisphosphonate Turnover in Fracture Repair in Rats.
Cantrill, LC; Little, DG; Mikulec, K; Murphy, CM; Peacock, L; Schindeler, A, 2015
)
0.42
" MCW measurements were retrospectively obtained from 197 DPRs of 66 children with OI types I, III, and IV who were in treatment with a comparable dosage of cyclical intravenous pamidronate between 2007 and 2013."( Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.
Acevedo, AC; Apolinário, AC; Castro, LC; Figueiredo, PT; Guimarães, AT; Leite, AF; Melo, NS; Paula, AP; Paula, LM, 2015
)
2.05
"In this retrospective study, 197 DPRs of 62 children with OI Types I, III and IV who were in treatment with a comparable dosage of intravenous PAM were selected."( Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment.
Acevedo, AC; Apolinário, AC; Castro, LC; de Melo, NS; de Paula, AP; de Paula, LM; de Souza Figueiredo, PT; Guimarães, AT; Leite, AF; Sindeaux, R, 2016
)
0.65
" The repeat dosing of Pam-Doxo-NPs in dogs with naturally occurring OS indicated the therapeutic was well tolerated without hematologic, nonhematologic, and cardiac toxicities."( Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis.
Borst, LB; Cai, K; Cheng, J; Dobrucki, LW; Fan, TM; Helferich, WG; Kamstock, D; Song, Z; Sternberg, R; Tang, L; Tong, R; Yang, X; Yin, Q, 2016
)
1.88
" This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain."( Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
Barlow, WE; Biermann, JS; Bosserman, LD; Clemons, MJ; Dhesy-Thind, SK; Dillmon, MS; Eisen, A; Frank, ES; Jagsi, R; Jimenez, R; Moy, B; Somerfield, MR; Theriault, RL; Van Poznak, C; Vandenberg, TA; Yee, GC, 2017
)
0.46
" Pre-treatment with the bisphosphonate pamidronate started at 4 weeks of age over a period of 2 weeks or 6 weeks (cumulative dose 8 mg/kg for both) to assess the effectiveness of the two dosing regimens in ameliorating glucocorticoid-induced bone loss."( Pre-treatment with Pamidronate Improves Bone Mechanical Properties in Mdx Mice Treated with Glucocorticoids.
Chen, J; Grynpas, MD; Mitchell, J; Yoon, SH, 2019
)
1.11
" The frequency of pamidronate dosage was dependent of patient's symptoms."( Treatment of chronic recurrent multifocal osteomyelitis with bisphosphonates in children.
Bień, S; Błażkiewicz, M; Ebisz, M; Jurczyk, M; Namyślak, M; Sułko, J, 2019
)
0.85
" At this point, closed fractures were made using an Einhorn apparatus, and bisphosphonate dosing was continued until the experimental endpoint."( Pretreatment with Pamidronate Decreases Bone Formation but Increases Callus Bone Volume in a Rat Closed Fracture Model.
Little, DG; McDonald, MM; Mikulec, K; Morse, A; Munns, CF; Schindeler, A, 2020
)
0.89
" In the absence of reported MRONJ cases, dental extractions should not be withheld because of previous antiresorptive exposure and antiresorptive medication dosing need not be altered in the pediatric population."( Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
Neal, TW; Schlieve, T, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phosphonoacetic acidA member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
geranyl diphosphate biosynthesis67

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency3.37800.000214.376460.0339AID720691
gemininHomo sapiens (human)Potency13.33590.004611.374133.4983AID624297
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency25.11890.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency19.95260.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Geranylgeranyl pyrophosphate synthaseHomo sapiens (human)IC50 (µMol)185.86650.00401.02764.5000AID1798541; AID391371; AID74507
Farnesyl pyrophosphate synthaseHomo sapiens (human)IC50 (µMol)1.07450.00020.71099.3600AID318593; AID318594; AID689987; AID72181; AID72667; AID72669
Farnesyl pyrophosphate synthaseHomo sapiens (human)Ki0.18910.00010.21651.9000AID318593; AID318594; AID72668
Farnesyl pyrophosphate synthase Leishmania donovaniKi0.19000.01100.07820.1900AID238531
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
isoprenoid metabolic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
geranyl diphosphate biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
geranylgeranyl diphosphate biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
farnesyl diphosphate biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
isoprenoid biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
cholesterol biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
geranyl diphosphate biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
farnesyl diphosphate biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
dimethylallyltranstransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
farnesyltranstransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
geranyltranstransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
protein bindingGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
identical protein bindingGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
metal ion bindingGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
prenyltransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
RNA bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
protein bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
metal ion bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
dimethylallyltranstransferase activityFarnesyl pyrophosphate synthaseHomo sapiens (human)
geranyltranstransferase activityFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleoplasmGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
cytoplasmGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
cytosolGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
Z discGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
perinuclear region of cytoplasmGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
nucleoplasmFarnesyl pyrophosphate synthaseHomo sapiens (human)
cytosolFarnesyl pyrophosphate synthaseHomo sapiens (human)
cytoplasmFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (177)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID74507Inhibitory activity against the human recombinant geranylgeranyl diphosphate synthase (GGPPSase).2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID71580pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
AID328057Cytotoxicity against streptomycin-resistant F plasmid deficient Escherichia coli JS42007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328055Inhibition of conjugate DNA transfer between tetracycline-resistant F plasmid positive Escherichia coli JS10 to streptomycin-resistant F plasmid deficient Escherichia coli JS42007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID238395Inhibition of hypoxanthine-guanine phosphoribosyltransferase (TcHPRT)2004Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
The purine transferase from Trypanosoma cruzi as a potential target for bisphosphonate-based chemotherapeutic compounds.
AID318595Inhibition of bone resorption in rat assessed as phosphate2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID96034Toxicity evaluated against human nasopharyngeal carcinoma KB cell line2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID208084In vitro growth inhibition of bloodstream-form Trypanosoma brucei rhodesiense Trypomastigotes2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID29611Bioavailability by the ratios of 14C p.o. /14C i.v. accumulated in bone at 24 hr (dose 10 mg/kg p.o.)2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
A peptide prodrug approach for improving bisphosphonate oral absorption.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328056Cytotoxicity against tetracycline-resistant F plasmid positive Escherichia coli JS102007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID758724Induction of apoptosis in human osteoclasts at 100 uM after 7 days using Hoechst 33258 staining2013European journal of medicinal chemistry, Jul, Volume: 65Low toxicity and unprecedented anti-osteoclast activity of a simple sulfur-containing gem-bisphosphonate: a comparative study.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26999Inhibition of HAP dissolution was determined in 3.87 mM calcium and 2.32 mM phosphate metastable solution at 0.24 mM concentration *: p<0.052000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
A peptide prodrug approach for improving bisphosphonate oral absorption.
AID318593Inhibition of human recombinant FPPS expressed in Escherichia coli BL212008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID244679Therapeutic index (TI) value as ratio of lethal dose (LD50) to the inhibitory concentration (IC50)2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
AID210170Effective dose after subcutaneous administration to TPTX rats for 50% reduction of hypercalcemia2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
AID197479Effective dose for increased urinary excretion of MDH in rats after a treatment period of 14 days in renal tolerability model2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
AID1894080Drug distribution in NMRI mouse liver at 4.2 mg/kg administered as C14-lableled compound and assessed as radioactivity and measured upto 2 hrs2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID28404Apical to basolateral fluxes across Caco-2 cell monolayers at 37 degree celsius was studied.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
A peptide prodrug approach for improving bisphosphonate oral absorption.
AID72667Inhibitory activity against farnesyl Pyrophosphate Synthase was determined2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID184809Bone resorption activity in rats.2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID270725Antiproliferative activity against rat 13762 cell line2006Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19
Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines.
AID249161Lethal dose required to inhibit the growth of human KB (nasopharyngeal carcinoma) cell line2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
AID28262Inhibition of HAP formation, by the compound (1.0 mM) absorbed, was obtained in vitro studies.*: p<0.052000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
A peptide prodrug approach for improving bisphosphonate oral absorption.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID758725Antiosteoclast activity in human PBMC assessed as reduction of osteoclasts formation by measuring TRAcP positive multinucleated cells at 10 uM after 7 days2013European journal of medicinal chemistry, Jul, Volume: 65Low toxicity and unprecedented anti-osteoclast activity of a simple sulfur-containing gem-bisphosphonate: a comparative study.
AID689987Inhibition of recombinant human FPPS expressed in Escherichia coli by scintillation counting2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry.
AID328053Inhibition of Escherichia coli F plasmid TraI relaxase Y16F mutant assessed as oriT ssDNA cleavage at 200 nM2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID210617Inhibition of Toxoplasma gondii tachyzoites in human foreskin fibroblast monolayer(DMEM with 10%fetal calf serum)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID689988Inhibition of bone resorption in rat2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID197321Effective dose for increased cancellous bone area in young interact rats after a treatment period of 10 days2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
AID328054Inhibition of Escherichia coli F plasmid TraI relaxase Y16F mutant assessed as oriT ssDNA cleavage at 200 nM2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID197465Effective dose for increased cancellous bone hydroxy proline in young interact rats after a treatment period of 10 days2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
AID71578Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
AID248772In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
AID95765Inhibition of L. donovani (Amastigotes) strain MHOM/ET/67/L82 maintained in pathogen free spleen from female golden hamsters; toxic2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID132683Inhibition of bone resorption in the calvaria assay of mouse2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID758721Inhibition of human osteoclast-mediated type 1 bone collagen degradation assessed as release of europium-labeled collagen fragments at 0.1 uM after 7 days by time-resolved fluorescence assay2013European journal of medicinal chemistry, Jul, Volume: 65Low toxicity and unprecedented anti-osteoclast activity of a simple sulfur-containing gem-bisphosphonate: a comparative study.
AID28263Inhibition of HAP formation, by the compound (0.1 mM) absorbed, was obtained in vitro studies.*: p<0.052000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
A peptide prodrug approach for improving bisphosphonate oral absorption.
AID275054Antibacterial activity against Escherichia coli W31102006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID132685Inhibition of mineralization in the calvaria assay of mouse2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID197478Effective dose for increased mucosal permeability of perfused ileal loop in rats after a treatment period of 2 hr in intestinal tolerability model2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
AID238531Binding affinity towards Farnesyl diphosphate synthase from leishmania major2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
AID72181Inhibitory activity against the human recombinant FPPSase (Farnesyl diphosphate) enzyme2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID197323Effective dose for increased cancellous bone calcium in young interact rats after a treatment period of 10 days2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID270724Antiproliferative activity against human SF-268 cell line by MTT assay2006Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19
Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines.
AID26998Inhibition of HAP dissolution was determined in 3.87 mM calcium and 2.32 mM phosphate metastable solution at 0.048 mM concentration *: p<0.052000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
A peptide prodrug approach for improving bisphosphonate oral absorption.
AID1894079Anti-osteoclast activity rat assessed as inhibition of bone resorption relative to control2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
AID158550In vitro growth inhibition against Plasmodium falciparum2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID9382850% lethal dose for inhibition of KB cells growth2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID151353Inhibition of Plasmodium falciparum 3D7 in erythrocytes2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID758723Proapoptotic activity in human osteoclasts at 10 uM after 7 days using Hoechst 33258 staining2013European journal of medicinal chemistry, Jul, Volume: 65Low toxicity and unprecedented anti-osteoclast activity of a simple sulfur-containing gem-bisphosphonate: a comparative study.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID758727Cytotoxicity against mouse L929 cells assessed as reduction of cell viability after 72 hrs by neutral-red uptake assay2013European journal of medicinal chemistry, Jul, Volume: 65Low toxicity and unprecedented anti-osteoclast activity of a simple sulfur-containing gem-bisphosphonate: a comparative study.
AID248139In vitro inhibitory concentration against bone resorption in 17 day old fetal mouse metatarsals2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID575994Antimalarial activity against Plasmodium berghei NK65 infected in human HepG2 cells after 48 hrs by RT-PCR2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID117725Mean reduction in parasitaemia of Plasmodium berghei ANKA suppressive test in mice (Mus musculus) (in vivo) at 25 mg/kg scheduled for 4 days2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID1894081Drug distribution in NMRI mouse spleen at 4.2 mg/kg administered as C14-lableled compound and assessed as radioactivity and measured upto 2 hrs2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID270723Antiproliferative activity against human NCI-H460 cell line by MTT assay2006Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19
Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID67525In vitro growth inhibition against Entamoeba histolytica2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID246048Effective concentration against human Gamma delta T cells2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
AID208218Log IC50 brucei Trypomastigotes2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID235219Therapeutic index measured as the ratio of LD50 (KB cells) to IC50 (T.b. rhodesiense)2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID208225Inhibition of Trypanosoma rhodesiense (strain STIB900) was determined using blood stream from trypomastigotes2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID247940Inhibitory concentration against Dictyostelium discoideum cell growth2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
AID197319Effective dose for increased radiographic bone density in young interact rats after a treatment period of 10 days2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID71581pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1226178Half life in human plasma at 1 mg/kg, iv2015ACS medicinal chemistry letters, Apr-09, Volume: 6, Issue:4
Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters.
AID72668Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID575995Cytotoxicity against human HepG2 cells after 22 hrs2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID197315Effective dose for increased serum urea level rats after a treatment period of 1 hr in renal tolerability model2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1699996Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility.
AID318594Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 after 10 mins2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID235770Therapeutic ratio comparing nephrotoxic potential versus bone antiresorptive potency ( reciprocal of ED50 (TPTX assay) / the total urinary malate dehydrogenase excretion)2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID348326Antiresorptive activity in thyroidparathyroidectomized sc dosed rat assessed as inhibition of 1,25-dihydroxyvitamin D3-induced hypercalcemia2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
Synthesis, properties, and perspectives of gem-diphosphono substituted-thiazoles.
AID214469Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID71579Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
AID213660In vitro antiparasitic activity against Trypanosoma cruzi (amastigotes)2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID55429Ability to inhibit growth of Dictostelium discoideum.2002Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
AID72669Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M)2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID231757Ratio of calvaria mineralization to calvaria bone resorption2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
AID28406Basolateral to apical fluxes across Caco-2 cell monolayers at 37 degree celsius was studied.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
A peptide prodrug approach for improving bisphosphonate oral absorption.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID270722Antiproliferative activity against human MCF7 cell line by MTT assay2006Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19
Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines.
AID18003Bioavailability by the ratios of 14C p.o. /14C i.v. accumulated in urine at 24 hr (dose 10 mg/kg p.o.)2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
A peptide prodrug approach for improving bisphosphonate oral absorption.
AID391371Inhibition of human recombinant geranylgeranyl diphosphate synthase2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.
AID1700032Cytotoxicity against human KKU-100 cells assessed as cell growth inhibition after 48 hrs2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility.
AID221770Effective concentration to activate gammadelta T cells2002Journal of medicinal chemistry, Oct-24, Volume: 45, Issue:22
Quantitative structure--activity relations for gammadelta T cell activation by phosphoantigens.
AID1798541GGPP Synthase Inhibition Assay from Article 10.1021/jm800325y: \\Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.\\2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,091)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990141 (6.74)18.7374
1990's553 (26.45)18.2507
2000's884 (42.28)29.6817
2010's437 (20.90)24.3611
2020's76 (3.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.53 (24.57)
Research Supply Index7.86 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index125.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (70.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials368 (16.58%)5.53%
Reviews234 (10.54%)6.00%
Case Studies509 (22.93%)4.05%
Observational1 (0.05%)0.25%
Other1,108 (49.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (36)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Pilot Trial of Intravenous Pamidronate for Low Back Pain [NCT01210599]Phase 1/Phase 244 participants (Actual)Interventional2004-04-30Completed
Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon/Thalidomide and Pamidronate for Patients With Multiple Myeloma [NCT00004088]Phase 277 participants (Actual)Interventional1999-04-13Completed
An Open-Label, Multicentre Trial to Evaluate the Time Associated With the Preparation and Administration of Denosumab and Pamidronate in Subjects With Solid Tumors and Metastatic Bone Disease in Canada [NCT02101164]Phase 40 participants (Actual)Interventional2014-11-30Withdrawn
A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH > 150pg/ml) on a Ciclosporin A and Glucocorticoid B [NCT00738257]Phase 4126 participants (Actual)Interventional2000-06-30Completed
Randomized, Multicentric Phase IV Clinical Trial for the Administration of Pamidronate in Breast Cancer Patients With Bone Metastases [NCT00128297]Phase 4152 participants (Actual)Interventional2000-10-18Completed
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Disodium Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant [NCT00657852]Phase 479 participants (Actual)Interventional2000-12-31Completed
Unrandomized, Open Label Single-center Study to Assess the Long Term Efficacy of Intravenous Bisphosphonates for Bone Marrow Edema in Patients With SAPHO Syndrome [NCT02544659]Phase 130 participants (Actual)Interventional2015-10-31Completed
[NCT00767169]Phase 216 participants (Actual)Interventional2008-10-31Completed
Prevention of Post Operative Bone Loss in Children [NCT00655681]24 participants (Actual)Interventional2007-09-30Completed
Phase 1 Study of the Effect of Local Pamidronate Application in Preventing Periprosthetic Bone Loss After Total Cemented Hip Arthroplasty [NCT00548288]Phase 140 participants (Anticipated)Interventional2007-11-30Not yet recruiting
Antiangiogenic Treatment Strategy With Metronomic Chemotherapy Regimen Combined With a Cox-2 Inhibitor and a Bisphosphonate for Patients With Metastatic Breast Cancer [NCT01067989]Phase 222 participants (Actual)Interventional2010-03-31Terminated(stopped due to No satisfactory acrual)
CHronic Nonbacterial Osteomyelitis International Registry (CHOIR) [NCT04725422]2,000 participants (Anticipated)Observational2018-08-01Recruiting
A Randomized, Double-blind, Placebo-controlled, Phase IV Trial Evaluating the Palliative Benefit of Either Continuing Pamidronate or Switching to Second-line Zoledronic Acid in Breast Cancer Patients With High-risk Bone Metastases. [NCT01907880]Phase 474 participants (Actual)Interventional2012-08-31Completed
The Use of Bisphosphonates in the Treatment of Avascular Necrosis of the Femoral Head [NCT02007915]20 participants (Actual)Interventional2009-07-31Terminated(stopped due to PI decision)
A Pragmatic Randomised, Multicentre Trial Comparing 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases From Either Castration-resistant Prostate Cancer or Breast Cancer - The REaCT-BTA Study [NCT02721433]Phase 4263 participants (Actual)Interventional2016-08-31Completed
Bisphosphonates in Multicentric Osteolysis, Nodulosis and Arthropathy (MONA) Spectrum Disorder - an Alternative Therapeutic Approach [NCT02823925]3 participants (Actual)Observational2013-02-28Completed
A Randomised Trial Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (REaCT-Hold BMA) [NCT04549207]Phase 4240 participants (Anticipated)Interventional2020-10-09Recruiting
[NCT01799616]Phase 248 participants (Anticipated)Interventional2013-01-31Recruiting
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation [NCT02074631]Phase 280 participants (Actual)Interventional2015-02-28Completed
A Pilot Trial of IV Pamidronate for Low Back Pain [NCT00101790]Phase 144 participants (Anticipated)Interventional2003-09-30Active, not recruiting
UARK 99-016, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Multiple Myeloma and Poor Hematopoietic Stem Cell Reserve [NCT00083408]Phase 220 participants Interventional1998-03-31Completed
Phase I Trial of Arsenic Trioxide in Combination With Pamidronate Disodium [NCT00124605]Phase 124 participants (Actual)Interventional2005-04-30Completed
An Open-Label, Pilot Study of Samarium - Sm 153 Lexidronam (Quadramet) in Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain [NCT00482378]Phase 1/Phase 239 participants (Anticipated)Interventional2005-03-21Completed
Osteopenia and Renal Osteodystrophy: Evaluation and Management [NCT00108394]Phase 40 participants Interventional2002-10-31Completed
Prevention of Steroid-Induced Osteoporosis in Children [NCT00022841]Phase 1/Phase 240 participants InterventionalTerminated(stopped due to Inadequate eligible subjects to expect sufficient numbers to analyse outcomes.)
A Randomized Phase III Trial Of Thalidomide (NSC # 66847) Plus Dexamethasone Versus Dexamethasone In Newly Diagnosed Multiple Myeloma [NCT00033332]Phase 30 participants Interventional2002-04-30Completed
Comparison Between Pamidronate and Zoledronic Acid for the Treatment of Heart and Lung Transplant Related Osteopaenia and Osteoporosis [NCT00164008]Phase 456 participants (Actual)Interventional2002-10-31Completed
Study Into the Effect of Pamidronate for the Prevention of Heterotopic Ossification in High-risk Patients: A Randomized Controlled Trial [NCT00262392]0 participants (Actual)Interventional2005-06-30Withdrawn
Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation [NCT00302627]43 participants (Actual)Interventional1999-01-31Completed
Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial [NCT01718951]Phase 430 participants (Actual)Interventional2012-08-31Completed
Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression [NCT02313727]Phase 430 participants (Anticipated)Interventional2014-12-31Not yet recruiting
A Phase II Multi-Institution Study of Docetaxel and Doxorubicin as Induction Therapy Followed by Sequential High Dose Chemotherapy and CD 34+ Selected Stem Cell Support for Women With Metastatic Breast Cancer [NCT00004906]Phase 20 participants Interventional1999-10-31Completed
Bisphosphonate Therapy for Osteogenesis Imperfecta [NCT00159419]Phase 418 participants (Actual)Interventional1999-08-31Completed
UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma [NCT00083382]Phase 283 participants (Actual)Interventional1998-12-31Completed
The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis. [NCT00376883]Phase 3500 participants Interventional2000-01-31Completed
A Trial of Pamidronate in Children With Osteogenesis Imperfecta [NCT00005901]Phase 334 participants (Actual)Interventional2000-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00004088 (2) [back to overview]Progression-free Survival
NCT00004088 (2) [back to overview]Three-year Overall Survival
NCT00005901 (6) [back to overview]Change in Bone Mineral Density in Response to Pamidronate
NCT00005901 (6) [back to overview]Change in Bone Mineral Density in Response to Pamidronate
NCT00005901 (6) [back to overview]Change in Bone Mineral Density in Response to Pamidronate
NCT00005901 (6) [back to overview]Change in Bone Mineral Density in Response to Pamidronate
NCT00005901 (6) [back to overview]Change in Bone Mineral Density in Response to Pamidronate
NCT00005901 (6) [back to overview]Change in Bone Mineral Density in Response to Pamidronate
NCT00083382 (1) [back to overview]Best Response
NCT00159419 (1) [back to overview]Bone Mineral Density
NCT00655681 (1) [back to overview]Amount of Bone Density Lost (%) From pre-to Post-operative DXA Scan

Progression-free Survival

"Kaplan-Meier estimate at three years post-first transplant of survival. Event of interest is the first of Death or Progression. Censoring is Alive in Continuous Complete Remission at date of last follow-up.~95 percent confidence interval of the point estimate is calculated using Greenwood's variance." (NCT00004088)
Timeframe: Estimate reported at three years after day 0 of the first cycle of infusion of cells of the tandem transplant.

Interventionproportion of participants (Number)
HD Chemo Followed by PBPC Rescue0.456

[back to top]

Three-year Overall Survival

Kaplan-Meier estimate at three years post-first transplant of survival. Outcome is death or alive at follow-up (censored). 95 percent confidence interval of the point estimate is calculated using Greenwood's variance. (NCT00004088)
Timeframe: Estimate reported at three years after day 0 of the first cycle of infusion of cells of the tandem transplant.

Interventionproportion of participants (Number)
HD Chemo Followed by PBPC Rescue0.662

[back to top]

Change in Bone Mineral Density in Response to Pamidronate

Dual-energy X-ray Absorptiometry (DXA) measurements were obtained using a Hologic QDR 4500 densitometer and low density software package. Measurements have a precision of 0.011 SD. Raw measurements were converted to Z-scores for analysis using the manufacturer's reference standards for age and pubertal status. (NCT00005901)
Timeframe: Baseline vs. 12 months after first dose

InterventionZ-score (Mean)
Pamidronate Every 3 Months for 3 Years-3.54
Pamidronate Every 6 Months for 3 Years-4.98

[back to top]

Change in Bone Mineral Density in Response to Pamidronate

Dual-energy X-ray Absorptiometry (DXA) measurements were obtained using a Hologic QDR 4500 densitometer and low density software package. Measurements have a precision of 0.011 SD. Raw measurements were converted to Z-scores for analysis using the manufacturer's reference standards for age and pubertal status. (NCT00005901)
Timeframe: Baseline vs. 18 months after first dose

InterventionZ-score (Mean)
Pamidronate Every 3 Months for 3 Years-3.71
Pamidronate Every 6 Months for 3 Years-4.65

[back to top]

Change in Bone Mineral Density in Response to Pamidronate

Dual-energy X-ray Absorptiometry (DXA) measurements were obtained using a Hologic QDR 4500 densitometer and low density software package. Measurements have a precision of 0.011 SD. Raw measurements were converted to Z-scores for analysis using the manufacturer's reference standards for age and pubertal status. (NCT00005901)
Timeframe: Baseline vs. 24 months after first dose

InterventionZ-score (Mean)
Pamidronate Every 3 Months for 3 Years-3.48
Pamidronate Every 6 Months for 3 Years-4.7

[back to top]

Change in Bone Mineral Density in Response to Pamidronate

Dual-energy X-ray Absorptiometry (DXA) measurements were obtained using a Hologic QDR 4500 densitometer and low density software package. Measurements have a precision of 0.011 SD. Raw measurements were converted to Z-scores for analysis using the manufacturer's reference standards for age and pubertal status. (NCT00005901)
Timeframe: Baseline vs. 30 months after first dose

InterventionZ-score (Mean)
Pamidronate Every 3 Months for 3 Years-3.48
Pamidronate Every 6 Months for 3 Years-4.05

[back to top]

Change in Bone Mineral Density in Response to Pamidronate

Dual-energy X-ray Absorptiometry (DXA) measurements were obtained using a Hologic QDR 4500 densitometer and low density software package. Measurements have a precision of 0.011 SD. Raw measurements were converted to Z-scores for analysis using the manufacturer's reference standards for age and pubertal status. (NCT00005901)
Timeframe: Baseline vs. 36 months after first dose

InterventionZ-score (Mean)
Pamidronate Every 3 Months for 3 Years-3.31
Pamidronate Every 6 Months for 3 Years-4.18

[back to top]

Change in Bone Mineral Density in Response to Pamidronate

Dual-energy X-ray Absorptiometry (DXA) measurements were obtained using a Hologic QDR 4500 densitometer and low density software package. Measurements have a precision of 0.011 SD. Raw measurements were converted to Z-scores for analysis using the manufacturer's reference standards for age and pubertal status. (NCT00005901)
Timeframe: Baseline vs. 6 months after first dose

InterventionZ-score (Mean)
Pamidronate Every 3 Months for 3 Years-4.01
Pamidronate Every 6 Months for 3 Years-4.98

[back to top]

Best Response

"Best response to study treatment as defined by protocol-specific response criteria:~Complete Response (CR) = absence of urine and serum M-components by immunofixation; bone marrow should be adequately cellular (>20%) with <1% monoclonal plasma cells by DNA-clg flow cytometry; serum calcium level must be normal; no new bone lesions nor enlargement of existing lesions; Normalization of serum concentrations of normal immunoglobulins is not required for CR. Partial Response (PR) = Reduction by > 75% in serum myeloma protein production; Decrease in monoclonal marrow plasmacytosis to <5%; Decrease in Bence-Jones proteinuria by >90%; No new lytic bone lesions or soft tissue plasmacytoma.~Treatment Failures/Progressive Disease (PD) = Such patients do not fulfill the above criteria and/or have new lytic lesions (but not compression fractures), hypercalcemia, or other new manifestations of disease." (NCT00083382)
Timeframe: 2 years

Interventionparticipants (Number)
Treatment Failure/Progressive DiseasePartial ResponseComplete Response
Thalidomide + Bisphosphonate561710

[back to top]

Bone Mineral Density

"By Dual-energy x-ray absorptiometry. Results were reported as z-scores as well as as absolute values. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate a better outcome, or similar, as accurate and appropriate." (NCT00159419)
Timeframe: 2 years

Interventionz-score (Mean)
Pamidronate Treatment-1.3
Alendronate-1.1

[back to top]

Amount of Bone Density Lost (%) From pre-to Post-operative DXA Scan

"Mean change lumbar spine post-op BMD Mean Right metaphyseal femur change post op BMD Mean Right transitional femur change post op BMD Mean Right diaphyseal femur change post op BMD~Mean Left metaphyseal femur change post op BMD Mean Left transitional femur change post op BMD Mean Left diaphyseal femur change post op BMD" (NCT00655681)
Timeframe: Preoperative to post-operative DXA scan (4-12 weeks)

Interventionpercent change (Mean)
A Patients Receiving Pamidronate0.043
B Patients Receiving Saline (Control Placebo)-0.025

[back to top]